EP2104512A2 - Proteines de streptococcus et leur utilisation comme vaccins - Google Patents

Proteines de streptococcus et leur utilisation comme vaccins

Info

Publication number
EP2104512A2
EP2104512A2 EP07874553A EP07874553A EP2104512A2 EP 2104512 A2 EP2104512 A2 EP 2104512A2 EP 07874553 A EP07874553 A EP 07874553A EP 07874553 A EP07874553 A EP 07874553A EP 2104512 A2 EP2104512 A2 EP 2104512A2
Authority
EP
European Patent Office
Prior art keywords
seq
amino acids
polypeptide
group
pho3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07874553A
Other languages
German (de)
English (en)
Inventor
Mark Redfern
Helen Harries
Joanne Bedwell
Steven Neville Chatfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development UK Ltd
Original Assignee
Emergent Product Development UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Development UK Ltd filed Critical Emergent Product Development UK Ltd
Publication of EP2104512A2 publication Critical patent/EP2104512A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/09—Lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Definitions

  • This invention relates to the identification of combinations of proteins, and their use as a vaccine, a process of making the vaccine, and a method for immunizing a human or animal against a condition related to Group B Streptococcus (GBS).
  • GBS Group B Streptococcus
  • GBS also known as Streptococcus agalactiae
  • Streptococcus agalactiae is the causative agent of various conditions.
  • GBS causes: Early onset neonatal infection.
  • This infection usually begins in utero or within five days of birth and causes severe septicaemia, meningitis, pneumonia, cellulitis, osteomyelitis, and septic arthritis in infants, which is lethal if untreated and even with treatment is associated with a 10-20% mortality rate.
  • Schuchat (1998) Clinic. Microbiol. Rev. 11(3): 497-513. Newborns with early-onset GBS disease acquire the organism intrapartum from their mothers, who are colonized with GBS in the genital track. See id. GBS colonizes the vagina of about 25% of young women, and approximately 1% of infants born via a vaginal birth to colonized mothers will become infected. See id. Late onset neonatal infection.
  • the late onset neonatal infection occurs in the period shortly after birth until about 3 months of age. It causes a septicaemia, which is complicated by meningitis in 90% of cases. Other focal infections also occur including pneumonia, cellulitis, osteomyelitis, septic arthritis, abscesses, endocarditis, epiglottitis, and endopthalmitis. Adult infections.
  • GBS causes chronic mastitis in cows. This, in turn, leads to reduced milk production and is therefore of considerable economic importance.
  • GBS is Gram positive coccus belonging to Lancei ⁇ eld group B.
  • serotypes based on their capsular polysaccharide structure (types Ia, Ib, Ia/c, II, III, IV, V, VI, VII, or VIII) identified to date. See Shet et al. (2004) Indian J. Med. Res. 120: 141-150.
  • types Ia, II, and III account for 85 percent of the isolates from infants. See id.
  • GBS serotypes Ia, III, and V (in a descending order) account for 78-87% of early onset invasive disease in newborn infants and parturient women.
  • the present invention is based on the identification of beneficial combinations of GBS' proteins which can be used to provide an immunogenic response, useful in therapy.
  • the composition provides an improved therapeutic effect compared to the single peptides.
  • the present invention is directed to a method of inducing an immune response against
  • Group B Streptococcus in an animal comprising administering to the animal in need thereof an effective amount of an isolated first polypeptide and an isolated second polypeptide, wherein each of the first polypeptide and the second polypeptide comprises an amino acid sequence at least 80% identical to a reference amino acid sequence selected from the group consisting of: (a) a Phol-13 polypeptide, which is selected from the group consisting of (i) SEQ ID NO: 2; (ii) amino acids 1-59 of SEQ ID NO: 2; (iii) amino acids 132-181 of SEQ ID NO: 2; (iv) amino acids 101- 181 of SEQ ID NO: 2; and (v) amino acids 1-181 of SEQ ID NO: 2; (b) a Phol-14 polypeptide, which is selected from the group consisting of (i) SEQ ID NO: 5 and (ii) amino acids 1-45 of SEQ ID NO: 5; (c) a Phol-5 polypeptide, which is selected from the group consisting of (i) SEQ ID NO
  • the present invention is directed to a method of inducing an immune response against Group B Streptococcus in an animal comprising administering to the animal in need thereof an effective amount of an isolated first polynucleotide encoding the first polypeptide described above and an isolated second polynucleotide encoding the second polypeptide described above.
  • the immune response induced by the first polynucleotide and the second polynucleotide prevents, treats, or ameliorates a condition or disorder associated with Group B Streptococcal infection in the animal.
  • the first polynucleotide and the second polynucleotide may be located in one or more expression vectors. More than one expression vectors may be identical or different or a combination thereof.
  • Streptococcus in an animal comprises administering to the animal in need thereof an effective amount of an isolated first antibody or antigen binding fragment thereof raised against the first polypeptide described herein and an isolated second antibody or antigen binding fragment thereof raised against the second polypeptide described herein.
  • the immune response prevents, treats, or ameliorates a condition or disorder associated with Group B Streptococcal infection in the animal.
  • the method of inducing an immune response further comprises administering an isolated third polypeptide, an isolated third antibody or antigen-binding fragment thereof raised against an isolated third polypeptide, or an isolated third polynucleotide.
  • the third polynucleotide described herein may comprise a promoter operably linked to the first polynucleotide or the second polynucleotide.
  • the third polynucleotide may encode a third polypeptide.
  • the third polypeptide may be an antigenic or immunogenic polypeptide, e.g., a polypeptide derived from a bacterium, a virus, a fungus, or a protozoan.
  • the antigenic or immunogenic polypeptide may be derived from Group B Streptococcus.
  • the third polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (a) a Phol-13 polypeptide, which is selected from the group consisting of (i) SEQ ID NO: 2; (ii) amino acids 1-59 of SEQ ID NO: 2; (iii) amino acids 132-181 of SEQ ID NO: 2; (iv) amino acids 101-181 of SEQ ID NO: 2; and (v) amino acids 1-181 of SEQ ID NO: 2; (b) a Phol-14 polypeptide, which is selected from the group consisting of (i) SEQ ID NO: 5 and (ii) amino acids 1-45 of SEQ ID NO: 5;(c) a Phol-5 polypeptide, which is selected from the group consisting of (i) SEQ ID NO: 8; (a Phol-13
  • SEQ DD NO: 18 (g) a Pho2-2 polypeptide, which is selected from the group consisting of (i) SEQ DD NO: 21; (ii) amino acids 1 -77 of SEQ DD NO: 21; (iii) amino acids 106- 225 of SEQ DD NO:21; (iv) amino acids 272-360 of SEQ DD NO:21; and (v) amino acids 106-360 of SEQ DD NO:21; (h) a Pho3-14 polypeptide, which is selected from the group consisting of: (i) SEQ DD NO: 24; (ii) amino acids 43-84 of SEQ DD NO: 24; (iii) amino acids 1-84 of SEQ DD NO: 24; (iv) amino acids 88-122 of SEQ DD NO: 24; and (v) amino acids 38-122 of SEQ DD NO: 24; (i) a Pho3-17 polypeptide, which is selected from the group consisting of: (i) SEQ DD NO:
  • the first polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ED NO: 33; (ii) amino acids 113-192 of SEQ ED NO: 33; (iii) amino acids 71-192 of SEQ ED NO: 33; and (iv) amino acids 24-192 of SEQ ED NO: 33; and the second polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ED NO: 21; (ii) amino acids 1-77 of SEQ ED NO: 21; (iii) amino acids 106-225 of SEQ ED NO: 21; (iv) amino acids 272-360 of SEQ ED NO: 21; and (v) amino acids 106-360 of SEQ
  • the present invention includes a method comprising administering an isolated first polypeptide and an isolated second polypeptide, wherein the first polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 33; (ii) amino acids 113-192 of SEQ E) NO: 33; (iii) amino acids 71-192 of SEQ ID NO: 33; and (iv) amino acids 24-192 of SEQ E) NO: 33; and the second polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ E) NO: 68, (ii) amino acids 1-138 of SEQ E) NO: 68; (iii) amino acids 285-363 of SEQ E) NO: 68; (iv) amino acids 210-363
  • the method of the present invention comprises administering an isolated first polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ E) NO: 21; (ii) amino acids 1-77 of SEQ E) NO: 21; (iii) amino acids 106- 225 of SEQ E) NO:21; (iv) amino acids 272-360 of SEQ E) NO:21; and (v) amino acids 106-360 of SEQ E) NO:21; and an isolated second polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ E) NO: 68, (ii) amino acids 1-138 of SEQ E) NO: 68; (iii) amino acids 285-363 of SEQ E) NO: 68; (i) SEQ E) NO:
  • the present invention includes a method of inducing an immune response comprising administering an isolated first polypeptide, an isolated second polypeptide, and an isolated third polypeptide, wherein the first polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ E) NO: 33; (ii) amino acids 113-192 of SEQ E) NO: 33; (iii) amino acids 71-192 of SEQ E) NO: 33; and (iv) amino acids 24-192 of SEQ E ) NO: 33, the second polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ E) NO: 21; (ii) amino acids 1-77 of SEQ E) NO: 21; (iii) amino acids 106-225 of SEQ E) NO
  • the method may further comprise administering one or more carriers or one or more adjuvants, e.g., Alum and a CPG oligonucleotide.
  • one or more carriers or one or more adjuvants e.g., Alum and a CPG oligonucleotide.
  • the method of the present invention induces an immune response when administered in an animal in need thereof.
  • the immune response may be a humoral immune response or a cell- mediated immune response or a combination thereof.
  • the first polypeptide, the first polynucleotide, or the first antibody or antigen binding fragment thereof may be administered prior to or simultaneously with the second polypeptide, second polynucleotide, or second antibody or antigen binding fragment thereof.
  • the second polypeptide, second polynucleotide, or second antibody or antigen binding fragment thereof may be administered prior to the first polypeptide, the first polynucleotide, or the first antibody or antigen binding fragment thereof.
  • the polypeptides, polynucleotides or antibody or antigen binding fragment thereof can be administered as one or multiple doses.
  • polypeptides, polynucleotides, or antibody or antigen-binding fragment thereof used in the present invention may be administered via intramuscular injection, subcutaneous injection, intra-dermal injection, intradural injection, intravenous injection, oral administration, mucosal administration, intranasal administration, or pulmonary administration.
  • the present invention also includes a composition comprising an isolated first polypeptide and an isolated second polypeptide, a composition comprising an isolated first polynucleotide encoding the first polypeptide and an isolated second polynucleotide encoding the second polypeptide, and a composition comprising an isolated first antibody or antigen-binding fragment thereof specifically binds the first polypeptide and an isolated second antibody or antigen binding fragment thereof specifically binds the second polypeptide described herein.
  • composition comprising an isolated first polypeptide and an isolated second polypeptide, an isolated first antibody or antigen binding fragment thereof and an isolated second antibody or antigen binding fragment thereof, or an isolated first polynucleotide and an isolated second polynucleotide further comprises an isolated third polypeptide, an isolated third antibody or antigen-binding fragment thereof raised against a third polypeptide, or an isolated third polynucleotide, respectively.
  • the third polynucleotide may encode a third polypeptide.
  • the third polypeptide used in the present invention may be an antigenic or immunogenic polypeptide, e.g., a polypeptide derived from Group B Streptococcus.
  • the third polypeptide used in the present invention may be the GBS polypeptides, fragments, derivatives, or variants thereof.
  • the composition comprises an isolated first polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 33; (ii) amino acids 113-192 of SEQ ID NO: 33; (iii) amino acids 71-192 of SEQ ID NO: 33; and (iv) amino acids 24-192 of SEQ ID NO: 33; and an isolated second polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 21; (ii) amino acids 1-77 of SEQ ED NO: 21; (iii) amino acids 106-225 of SEQ ID NO
  • the composition comprises an isolated first polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ED NO: 33; (ii) amino acids 113-192 of SEQ ID NO: 33; (iii) amino acids 71-192 of SEQ ID NO: 33; and (iv) amino acids 24-192 of SEQ ID NO: 33; and an isolated second polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 68, (ii) amino acids 1-138 of SEQ ID NO: 68; (iii) amino acids 285-363 of SEQ DD NO: 68; (iv) amino acids 210-363 of SEQ DD NO: 68; (v) amino acids 210-444 of S
  • the composition comprises an isolated first polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ DD NO: 21; (ii) amino acids 1-77 of SEQ DD NO: 21; (iii) amino acids 106-225 of SEQ DD NO:21; (iv) amino acids 272-360 of SEQ DD NO:21; and (v) amino acids 106-360 of SEQ DD NO:21 ; and an isolated second polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ DD NO: 68, (ii) amino acids 1-138 of SEQ DD NO: 68; (iii) amino acids 285-363 of SEQ DD NO: 68; (iv) amino acids 210-3
  • the composition comprises an isolated first polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ DD NO: 33; (ii) amino acids 113-192 of SEQ DD NO: 33; (iii) amino acids 71-192 of SEQ DD NO: 33; and (iv) amino acids 24-192 of SEQ DD NO: 33; an isolated second polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 21; (ii) amino acids 1-77 of SEQ ED NO: 21; (iii) amino acids 106-225 of SEQ ID NO:21; (iv) amino acids 272-360 of SEQ ID NO:21; and (v) amino acids 106-360 of SEQ ID NO:
  • composition of the present invention may further comprise one or more polysaccharides, carriers, or adjuvants, e.g., Alum and a CpG polynucleotide, or a combination thereof.
  • polysaccharides, carriers, or adjuvants e.g., Alum and a CpG polynucleotide, or a combination thereof.
  • composition of the present invention when administered in an animal, induces an immune response such as a humoral immune response or a cell-mediated immune response.
  • a composition comprises two or more of polypeptides, wherein the polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from the group consisting of Phol-13, Phol-14, Phol-5, Pho3-3 (phol-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3-29, Pho3-50, MS4, MSI l, MS14, MSlO(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, wherein the polypeptide is recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence.
  • a reference amino acid sequence selected from the group consisting of Phol-13, Phol-14, Phol-5,
  • a composition may comprise two or more of polynucleotides, wherein the polynucleotide comprises a nucleic acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference nucleic acid sequence encoding an amino acid sequence selected from group consisting of Phol-13, Phol-14, Phol-5, Pho3-3 (phol-7), Pho2-10, Pho2- 15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3- 23, Pho3-24, Pho3-29, Pho3-50, MS4, MSI l, MS14, MSlO(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, wherein the polynucleotide encodes a polypeptide recognizable by an antibody preparation that specifically binds to a polypeptide consisting
  • composition of the present invention may comprise two or more of vectors, wherein the vector encodes a polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from group consisting of Phol-13, Phol-14, Phol-5, Pho3-3 (phol-7), Pho2-10, Pho2- 15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3- 23, Pho3-24, Pho3-29, Pho3-50, MS4, MSI l, MS14, MSlO(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, wherein the polypeptide is recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence.
  • a reference amino acid sequence selected from group consisting of Phol-13, Phol-14
  • a composition may comprise two or more of host cells, wherein the host cell comprises a vector encoding a polypeptide comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from group consisting of Phol-13, Phol-14, Phol-5, Pho3-3 (phol-7), Pho2- 10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3- 22, Pho3-23, Pho3-24, Pho3-29, Pho3-50, MS4, MSI l, MS14, MSlO(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, wherein the polypeptide is recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence.
  • a reference amino acid sequence selected from group consisting of Phol-13
  • a composition may comprise antibodies raised against two or more of polypeptides, wherein the polypeptide comprises an amino acid sequence at least 80%, at least 90%, at least 95%, at least 98%, or 100% identical to a reference amino acid sequence selected from group consisting of Phol-13, Phol-14, Phol-5, Pho3-3 ( ⁇ hol-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3-29, Pho3-50, MS4, MSI l, MS14, MSlO(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, wherein the polypeptide is recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence.
  • a reference amino acid sequence selected from group consisting of Phol-13, Phol-14, Phol
  • composition of the present invention further comprises a carrier, an , adjuvant, or a targeting molecule.
  • the present invention also includes a diagnostic reagent comprising the composition of the present invention described herein.
  • the present invention includes a method of detecting anti-Group B
  • Streptococcus antibodies in a test sample comprising the steps of (a) contacting the sample with the composition described herein to form Group B Streptococcus antigen: anti-Group B Streptococcus antibody immunocomplexes; and (b) detecting the presence of or measuring the amount of the immunocomplexes formed during step (a) or a diagnostic kit for detecting an antibody or antigen-binding fragment thereof to Group B Streptococcus, wherein the kit comprises the composition described elsewhere herein, a container means for contacting the polypeptide or composition with a test sample, and a reagent means for detecting or measuring Group B Streptococcus antigen: anti-Group B Streptococcus antibody immunocomplexes formed between the polypeptide and the antibody or antigen-binding fragment thereof.
  • BRIEF DESCRIPTION OF THE DRAWINGS BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A depicts the Hopp/Woods antigenicity profile of the GBS polypeptides: IA:
  • Figure 2 depicts Opsonophagocytosis of Group B Streptococcus strain A909 opsonised with monkey sera raised against GBS vaccine comprising Pho 3-1 (SEQ ID NO: 33) and MSlO (NPGAP: SEQ ID NO: 68).
  • the present invention is directed to polypeptides and polynucleotides derived from GBS strains, composition comprising the polypeptides and polynucleotides, and methods of administering the composition to prevent or treat diseases related to Group B Streptococcus infection.
  • Organisms likely to contain the polypeptides include, but are not limited to, Enterococcus species ⁇ e.g., Enterococcus faecalis or Enterococcus faecium), Lactobacillus species ⁇ e.g.
  • Lactobacillus casei, Lactobacillus sakei, or Lactobacillus salivarius Lactococcus species ⁇ e.g., Lactococcus lactis), Leuconostoc species ⁇ e.g., Leuconostoc mesenteroides), Oenococcus species ⁇ e.g., Oenococcus oeni), Pediococcus species ⁇ e.g., Pediococcus pentosaceus), Staphylococcus species ⁇ e.g., Staphylococcus aureus or Staphylococcus epidermidis), or Streptococcus species ⁇ e.g., Streptococcus agalatiae, Streptococcus bovis, Streptococcus equi, Streptococcus gordonii, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus pneumonia
  • Vaccines to each of these organisms may be developed in the same way as described for
  • a or “an” entity refers to one or more of that entity; for example, “a polynucleotide,” is understood to represent one or more polynucleotides. As such, the terms “a” (or “an”), “one or more,” and “at least one” can be used interchangeably herein.
  • nucleic acid or “nucleic acid fragment” refers to any one or more nucleic acid segments, e.g., DNA or RNA fragments, present in a polynucleotide or construct.
  • Two or more, nucleic acids of the present invention can be present in a single polynucleotide construct, e.g., on a single plasmid, or in separate (non-identical) polynucleotide constructs, e.g., on separate plasmids.
  • any nucleic acid or nucleic acid fragment may encode a single polypeptide, e.g.
  • a single antigen, cytokine, or regulatory polypeptide may encode more than one polypeptide, e.g., a nucleic acid may encode two or more polypeptides.
  • a nucleic acid may encode a regulatory element such as a promoter or a transcription terminator, or may encode a specialized element or motif of a polypeptide or protein, such as a secretory signal peptide or a functional domain.
  • polynucleotide refers to an isolated molecule or construct, e.g., a virus genome (e.g., a non-infectious viral genome), messenger RNA (mRNA), plasmid DNA (pDNA), or derivatives of pDNA (e.g., minicircles as described in (Darquet, A-M et al, Gene Therapy 4:1341-1349 (1997)) comprising a polynucleotide.
  • virus genome e.g., a non-infectious viral genome
  • mRNA messenger RNA
  • pDNA plasmid DNA
  • derivatives of pDNA e.g., minicircles as described in (Darquet, A-M et al, Gene Therapy 4:1341-1349 (1997) comprising a polynucleotide.
  • a polynucleotide may be provided in linear (e.g., mRNA), circular (e.g., plasmid), or branched form as well as double- stranded or single-stranded forms.
  • a polynucleotide may comprise a conventional phosphodiester bond or a non-conventional bond (e.g., an amide bond, such as found in peptide nucleic acids (PNA)).
  • PNA peptide nucleic acids
  • polypeptide is intended to encompass a singular “polypeptide” as well as plural “polypeptides,” and comprises any chain or chains of two or more amino acids.
  • terms including, but not limited to “peptide,” “dipeptide,” “tripeptide,” “protein,” “amino acid chain,” or any other term used to refer to a chain or chains of two or more amino acids are included in the definition of a “polypeptide,” and the term “polypeptide” may be used instead of, or interchangeably with any of these terms.
  • polypeptides which have undergone post-translational modifications, for example, glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, or modification by non-naturally occurring amino acids.
  • GNS polypeptide encompasses full length polypeptide, serotypic, and other variants of full length polypeptide, fragments of full length polypeptide, serotypic or other variants of fragments of full length polypeptide, derivatives of full-length polypeptide, derivatives of fragments of full-length polypeptide, analogues of full-length polypeptide, analogues of fragments of full-length polypeptide, and chimeric and fusion polypeptide comprising full length polypeptide or one or more fragments of full length polypeptide.
  • fragment when referring to GBS polypeptides , of the present invention include any polypeptides which retain at least some of the, immunogenicity or antigenicity of the naturally-occurring proteins.
  • Fragments of GBS polypeptides of the present invention include proteolytic fragments, deletion fragments and, in particular, fragments which exhibit increased solubility during expression, purification, and/or administration to an animal. Fragments of GBS polypeptides further include proteolytic fragments or deletion fragments which exhibit reduced pathogenicity when delivered to a subject.
  • Polypeptide fragments further include any portion of the polypeptide which comprises an antigenic or immunogenic epitope of the native polypeptide, including linear as well as three- dimensional epitopes.
  • An “epitopic fragment” of a polypeptide antigen is a portion of the antigen that contains an epitope.
  • An “epitopic fragment” may, but need not, contain amino acid sequence in addition to one or more epitopes.
  • variant refers to a polypeptide that differs from the recited polypeptide due to amino acid substitutions, deletions, insertions, and/or modifications. Variants may occur naturally, such as a serotypic variant.
  • serotypic variant is intended polypeptides or polynucleotides that are present in a different GBS serotype. The serotypic variants are naturally occurring variants, but it can also be produced using art-known mutagenesis techniques. In the case of GBS, at least nine different serotypes, or "serotypic variants,” have been identified.
  • GBS serotypes include, but not limited to, serotypes Ia, Ib, Ia/c, II, III, IV, V, VI, VII, and VIII. There may be sequence variations between serotypes in some genes, for example, the genes encoding GBS Phol-13, Phol-14, Phol-5, Pho3-3 (phol-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3-29, Pho3-50, MS4, MSI l, MS16, MS14, MSlO(NP GAP, ME:NAP), PBP, pho 3-9, OCT, and PGK polypeptide.
  • Table 5 shows that an amino acid sequence of Phol-13 of GBS serotype III strain M732 have 98% homology to an amino acid sequence of the polypeptide found in GBS sero
  • Naturally occurring variants can also be found in related bacteria, e.g., Streptococcus agalatiae, Streptococcus bovis, Streptococcus equi, Streptococcus gordonii, Streptococcus mitis, Streptococcus /nutans, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus ratti, Streptococcus salivarius, Streptococcus suis, or Streptococcus thermophilus.
  • Polypeptides having homology to the GBS polypeptides can be found in these microorganisms.
  • Non-naturally occurring variants may be produced using art-known mutagenesis techniques.
  • variant polypeptides differ from an identified sequence by substitution, deletion or addition of five amino acids or fewer.
  • Such variants may generally be identified by modifying a polypeptide sequence, and evaluating the antigenic properties of the ⁇ modified polypeptide using, for example, the representative procedures described herein.
  • Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:
  • Polypeptide variants preferably exhibit at least about 60-70%, for example 75%, 80%,
  • variant polypeptides may comprise conservative or non-conservative amino acid substitutions, deletions or additions.
  • Derivatives of GBS polypeptides of the present invention are polypeptides which have been altered so as to exhibit additional features not found on the native polypeptide. Examples include fusion proteins.
  • An analog is another form of the GBS polypeptides of the present invention. An example is a proprotein which can be activated by cleavage of the proprotein to produce an active mature polypeptide.
  • Variants may also, or alternatively, contain other modifications, whereby, for example, a polypeptide may be conjugated or coupled, e.g., fused to a heterologous polypeptide, e.g., a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post- translationally directs transfer of the protein.
  • the polypeptide may also be conjugated or produced coupled to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., 6-His), or to enhance binding of the polypeptide to a solid support.
  • a polypeptide may be conjugated or coupled to an immunoglobulin Fc region.
  • the polypeptide may also be conjugated or coupled to a sequence that imparts or modulates the immune response to the polypeptide (e.g. a T-cell epitope, B-cell epitope, cytokine, chemokine, etc.) and/or enhances uptake and/or processing of the polypeptide by antigen presenting cells or other immune system cells.
  • the polypeptide may also be conjugated or coupled to other polypeptides/epitopes from GBS and/or from other bacteria and'or other viruses to generate a hybrid immunogenic protein that alone or in combination with various adjuvants can elicit protective immunity to other pathogenic organisms.
  • an "isolated" GBS polypeptide or a fragment, variant, or derivative thereof is intended a GBS polypeptide or protein that is not in its natural form. No particular level of purification is required.
  • an isolated GBS polypeptide can be removed from its native or natural environment.
  • Recombinantly produced GBS polypeptides and proteins expressed in host cells are considered isolated for purposes of the invention, as are native or recombinant GBS polypeptides which have been separated, fractionated, or partially or substantially purified by any suitable technique.
  • an isolated GBS polypeptide or protein can be provided as a live or inactivated expression vector expressing an isolated GBS polypeptide and can include those found in inactivated GBS vaccine compositions.
  • sequence identity refers to a relationship between two or more polynucleotide sequences or between two or more polypeptide sequences.
  • sequence identity is used herein interchangebly with the terms “sequence similarity” or “sequence homology.” When a position in one sequence is occupied by the same nucleic acid base or amino acid residue in the corresponding position of the comparator sequence, the sequences are said to be “identical” at that position.
  • the percentage “sequence identity” is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of "identical” positions.
  • the number of "identical” positions is then divided by the total number of positions in the comparison window and multiplied by 100 to yield the percentage of "sequence identity.” Percentage of "sequence identity” is determined by comparing two optimally aligned sequences over a comparison window (e.g., SEQ ID NO: 2 and a homologous polypeptide from another GBS isolate).
  • a comparison window e.g., SEQ ID NO: 2 and a homologous polypeptide from another GBS isolate.
  • the portion of a polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions termed gaps while the reference sequence (e.g. SEQ ID NO: 2) is kept constant.
  • An optimal alignment is that alignment which, even with gaps, produces the greatest possible number of "identical” positions between the reference and comparator sequences.
  • Sequence identity between two sequences can be determined using the version of the program "BLAST 2 Sequences" which was available from the National Center for Biotechnology Information as of September 1, 2004, which program incorporates the programs BLASTN (for nucleotide sequence comparison) and BLASTP (for polypeptide sequence comparison), which programs are based on the algorithm of Karlin and Altschul (Proc. Natl. Acad. ScL USA 90(12):5873-5877, 1993).
  • BLASTN for nucleotide sequence comparison
  • BLASTP for polypeptide sequence comparison
  • polypeptide or “at least two different polynucleotide,” as used herein, refers to the polypeptides or polynucleotides comprising two or more polypeptides or polynucleotide, respectively, that are not identical.
  • first polypeptide and the second polypeptide have no homology or less than 100% homology or identity to each other.
  • at least two different is used herein interchangeably with “at least two,” “more than one,” “two or more,” or “a combination of two or more.”
  • epitopes refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, for example a mammal, for example, a human.
  • An "immunogenic epitope,” as used herein, is defined as a portion of a protein that elicits an immune response in an animal, as determined by any method known in the art.
  • antigenic epitope as used herein, is defined as a portion of a protein to which an antibody or T-cell receptor can immunospecifically bind its antigen as determined by any method well known in the art. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Whereas all immunogenic epitopes are antigenic, antigenic epitopes need not be immunogenic.
  • a "coding region” is a portion of nucleic acid which consists of codons translated into amino acids. Although a “stop codon” (TAG, TGA, or TAA) is not translated into an amino acid, it may be considered to be part of a coding region, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, and the like, are outside the coding region.
  • compositions that are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity or other complications commensurate with a reasonable benefit/risk ratio, hi some embodiments, the polypeptide, polynucleotides, compositions, and vaccines of the present invention are pharmaceutically acceptable.
  • an "effective amount” is that amount the administration of which to an individual, either in a single dose or as part of a series, is effective for treatment or prevention.
  • An amount is effective, for example, when its administration results in a reduced incidence of Group B Streptococcus infection relative to an untreated individual, as determined two weeks after challenge with infectious GBS. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated ⁇ e.g. human, nonhuman primate, primate, etc.), the responsive capacity of the individual's immune system, the degree of protection desired, the formulation of the vaccine, a professional assessment of the medical situation, and other relevant factors.
  • a single dose is from about 10 ⁇ g to 10 mg/kg body weight of purified polypeptide or an amount of a modified carrier organism or virus, or a fragment or remnant thereof, sufficient to provide a comparable quantity of the recombinantly expressed GBS polypeptides.
  • peptide vaccine or "subunit vaccine” refers to a composition comprising one or more polypeptides of the present invention, which when administered to an animal are useful in stimulating an immune response against GBS infection.
  • additive effect refers to the effect, e.g., raising an immune response, that is the sum of the effects of two or more polypeptides acting independently.
  • immunized sera raised against the Pho3-1 polypeptide and the MSlO polypeptide separately, opsonize GBS and result in about 10% GBS uptake and in about 15% GBS uptake, respectively, immunized sera raised against both the Pho3- 1 polypeptide and MSlO polypeptide together opsonize GBS and result in about 25% GBS uptake.
  • the term "synergistic effect” or “synergy” is used herein to denote the effect that is more than additive, i.e., the combined immunostimulatory effect is greater than the expected total stimulatory effect calculated on the basis of the sum of the effects resulting from two or more polypeptides acting independently.
  • the immunized sera raised against both the Pho3-1 polypeptide and MSlO polypeptide together in the above example may opsonize GBS and result in more than 25% GBS uptake.
  • subject is meant any subject, particularly a mammalian subject, for whom diagnosis, prognosis, immunization, or therapy is desired.
  • Mammalian subjects include, but are not limited to, humans, domestic animals, farm animals, zoo animals such as bears, sport animals, pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, bears, cows; primates such as apes, monkeys, orangutans, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, donkeys, and zebras; food animals such as cows, pigs, and sheep; ungulates such as deer and giraffes; rodents such as mice, rats, hamsters and guinea pigs; and so on.
  • the animal is a human subject.
  • mammals and comprises mammals and birds, as well as fish, reptiles, and amphibians.
  • the term animal also encompasses model animals, e.g., disease model animals.
  • the term animal includes valuable animals, either economically or otherwise, e.g., economically important breeding stock, racing animals, shqw animals, heirloom animals, rare or endangered animals, or companion animals.
  • the mammal can be a human subject, a food animal or a companion animal.
  • an "subject in need thereof refers to an individual for whom it is desirable to treat, i.e., to prevent, cure, retard, or reduce the severity of disease symptoms related to GBS infection, and/or result in no worsening of GBS disease over a specified period of time.
  • priming or “primary” and “boost” or “boosting” as used herein to refer to the initial and subsequent immunizations, respectively, i.e., in accordance with the definitions these terms normally have in immunology. However, in certain embodiments, e.g., where the priming component and boosting component are in a single formulation, initial and subsequent immunizations may not be necessary as both the “prime” and the “boost” compositions are administered simultaneously.
  • passive immunity refers to the immunity to an antigen developed by a host animal, the host animal being given antibodies produced by another animal, rather than producing its own antibodies to the antigen.
  • active immunity refers to the production of an antibody by a host animal as a result of the presence of the target antigen.
  • the present invention includes a combination of more than two polypeptides, e.g., a combination of an isolated first polypeptide and an isolated second polypeptide.
  • the polypeptides, used as an isolated first polypeptide or an isolated second polypeptide comprises an amino acid sequence at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence found in GBS serotype III strain M732, fragments, derivatives, or variants thereof.
  • Variants commonly occur with many genes of simple, unicellular organisms. Examples of variants are serotypic variants. Another example of variants can be found within a same strain. For example, even within a same strain, different isolates obtained from different patients and/or geographical locations can exhibit some variation.
  • GBS outer membrane proteins or polypeptides and polynucleotides encoding the polypeptides or proteins are disclosed in International Appl. No. PCT/GB99/04377, filed December 22, 1999 and published as WO0037646 and International Appl. No. PCT/GB02/01089, filed March 11, 2002 and published as WO 02072623, both incorporated herein by reference in their entireties. Additional GBS outer surface proteins or polypeptides and polynucleotides are also disclosed in International Appl. No. PCT/GB99/04376, filed on December 22, 1999 and published as WO 00/37490 incorporated herein by reference in its entirety.
  • Phol-13 polypeptide sequence (SEQ ID NO: 2) found in GBS strain M732 is publicly available and have Accession No. CAC09086 in Genbank.
  • polynucleotide sequence encoding the Phol-13 polypeptide found in GBS M732 is publicly available as Accession No. AX026644 in Genbank and is designated herein as SEQ ID NO: 1.
  • Serotypic variants of the Phol-13 polypeptide can be found in other GBS strains.
  • the corresponding polypeptide found in GBS strain A909 is publicly available, and the locus tag is designated as SAK l600 (SEQ ID NO: 3).
  • the Phol-14 polypeptide sequence (SEQ ID NO: 5) found in GBS strain M732 is publicly available and has Accession No. CAC09087 in Genbank. [0081] SEQ ID NO: 5
  • the phol-14 polynucleotide sequence (SEQ ID NO: 4) encoding the Phol-14 polypeptide found in GBS strain M732 is publicly available and has Accession No. AX026646 in Genbank.
  • the Phol-5 polypeptide sequence (SEQ ID NO: 8) found in GBS strain M732 is a transglycosylase SLT domain family protein.
  • the polypeptide sequence is publicly available and has Accession No. CAC09088 in Genbank.
  • SEQ ID NO: 7 The phol-5 polynucleotide sequence (SEQ ID NO: 7) encoding the Phol-5 polypeptide found in GBS strain M732 is publicly available and has Accession No. AX026648 in Genbank. [0089] SEQ ID NO: 7
  • a serotypic variant of the Phol-5 polypeptide found in GBS strain A909 is publicly available and has locus tagNo. SAK_1205 (SEQ ID NO: 9). [0091] SEQ DD NO: 9
  • the pho3-3 polynucleotide sequence (SEQ DD NO: 10) encoding the Pho3-3 polypeptide found in GBS strain M732 is publicly available and has Accession No. AX026650 in Genbank. [0095] SEQDDNO: 10
  • a serotypic variant of the Pho3-3 polypeptide in GBS strain A909 is publicly available and has locus tag no. SAK_1286 (SEQ DD NO: 12). [0097] SEQDDNO: 12
  • the pho2-10 polynucleotide sequence (SEQ ID NO: 13) encoding the Pho2-10 polypeptides found in GBS strain M732 is publicly available and has Accession No. AX026652 in Genbank.
  • a serotypic variant of the Pho2-10 polypeptide is found in GBS strain A909 and has locus tag no. SAK_1175 (SEQ ID NO: 16).
  • the pho2-15 polynucleotide sequence (SEQ ED NO: 17) encoding the Pho2-15 polypeptide in GBS strain M732 is publicly available and has Accession No. AX026655 in Genbank.
  • a serotypic variant of the Pho2-15 polypeptide is found in GBS strain A909 and has locus tag no. SAKJ893 (SEQ E) NO: 19). [00111] SEQE)NO: 19
  • SEQ E The pho2-2 polynucleotide sequence (SEQ E) NO: 20) encoding the Pho2-2 polypeptide found in GBS strain M732 is publicly available and has Accession No. AX026657 in Genbank. [00115] SEQ E) NO: 20
  • a serotypic variant of the Pho2-2 polypeptide is found in GBS strain A909 and has locus tag no. SAK_O3O3 (SEQ ED NO: 22). [00117] SEQ ID NO: 22
  • the Pho3-14 polypeptide sequence (SEQ ID NO: 24) in GBS strain M732 is publicly available and has AccessionNo. CAC09094 in Genbank. [00119] SEQ ID NO: 24
  • the pho3-14 polynucleotide sequence (SEQ ID NO: 23) encoding the Pho3-14 polypeptide in GBS strain M732 is publicly available and has Accession No. AX026659 in Genbank.
  • a serotypic variant of the Pho3-14 polypeptide is found in GBS strain A909 and has locus tag no. SAK_2026 (SEQ ID NO: 25). [00123] SEQ ID NO: 25
  • the pho3-17 polynucleotide sequence (SEQ ID NO: 26) encoding the Pho3-17 polypeptide in GBS strain M732 is publicly available and has Accession No. AX026661 in Genbank.
  • a serotypic variant of the Pho3-17 polypeptide is found in GBS strain A909 and has locus tagno. SAK_0144 (SEQ E) NO: 28).
  • the pho3-18 polynucleotide sequence (SEQ E) NO: 29) encoding the Pho3-18 polypeptide in GBS strain M732 is publicly available and has Accession No. AX026663 in Genbank.
  • a serotypic variant of the Pho3-18 polypeptide is found in GBS strain A909 and has locus tagno. SAK_1796 (SEQ ID NO: 31). [00135] SEQK)NO: 31
  • the Pho3-1 polypeptide sequence (SEQ ID NO: 33) in GBS strain M732 is publicly available and has Accession No. CAC09097 in Genbank. [00137] SEQ ID NO: 33
  • pho3-l (ME: P31) polynucleotide sequence (SEQ ID NO: 32) encoding the Pho3-1 polypeptide in GBS strain M732 is publicly available and has Accession No. AX026665 ih Genbank.
  • a serotypic variant of the Pho3-1 is found in GBS strain A909 and has locus tag no.
  • Thepho3-21 (ME: P31) polynucleotide sequence (SEQ ID NO: 35) encoding the Pho3-21 polypeptide in GBS strain M732 is publicly available and has Accession No. AX026667 in Genbank.
  • a serotypic variant of the Pho3-21 polypeptide is found in GBS strain A909 and has locus tagno. SAK l656 (SEQ ID NO: 37). [00147] SEQ ID NO: 37:
  • the pho3-22 polynucleotide sequence (SEQ ID NO: 38) encoding the Pho3-22 polypeptide in GBS strain M732 is publicly available and has Accession No. AX026669 in Genbank.
  • a serotypic variant of the Pho3-22 polypeptide is found in GBS strain A909 and has locus tag no. SAK_0807 (SEQ ID NO: 40). [00153] SEQ ID NO: 40:
  • the Pho3-23 polypeptide sequence (SEQ ED NO: 42) in GBS strain M732 is publicly available and has locus tag No. CAC09100 in Genbank. [00155] SEQ ID NO: 42
  • the pho3-23 polynucleotide sequence (SEQ ID NO: 41) encoding the Pho3-23 polypeptide in GBS strain M732 is publicly available and has Accession No. AX026671 in Genbank.
  • a serotypic variant of the Pho3-23 polypeptide is found in GBS strain A909 and has locus tag no. SAKJ281 (SEQ ID NO: 43). [00159] SEQ ID NO: 43:
  • SEQ ID NO: 45 The Pho3-24 polypeptide sequence found in GBS strain M732 is publicly available and has Accession No. CAC09101 in Genbank. [00161] SEQ ID NO: 45 1 mfmgipqyff ylilavlpiy iglffkkrfa lyeiifslsf ivmmltgstf nqlksllayv
  • the pho3-24 polynucleotide sequence (SEQ ID NO: 44) encoding the Pho3-24 polypeptide in GBS strain M732 is publicly available and has Accession No. AX026673 in Genbank.
  • a serotypic variant of the Pho3-24 polypeptide is found in GBS strain A909 and has locus tag no. SAK_1811 (SEQ ID NO: 46). [00165] SEQ ID NO: 46:
  • the Pho3-29 polypeptide sequence (SEQ ID NO: 48) in GBS strain M732 is publicly available and has Accession No. CAC09102 in Genbank. [00167] SEQ ID NO: 48
  • the pho3-29 polynucleotide sequence (SEQ ID NO: 47) encoding the Pho3-29 polypeptide found in GBS strain M732 is publicly available and has Accession No. AX026675 in Genbank.
  • SEQ ID NO: 47 1 atgaataaaa taacgacatt atcaaccatc gccctgactt taatgctttg cgttggatgt 61 tctgccaata aagataatca aaaactaaa actgaggatc
  • a serotypic variant of the Pho3-29 polypeptide is found in GBS strain A909 and has locus tag no. SAK_0809 (SEQ ID NO: 49). [00171] SEQ ID NO: 49:
  • the pho3-50 polynucleotide sequence (SEQ ID NO: 50) encoding the Pho3-50 polypeptide in GBS strain M732 is publicly available and has Accession No. AX026677 in Genbank.
  • a serotypic variant of the Pho3-50 polypeptide is found in GBS strain A909 and has locus tag no. SAK 0890 (SEQ ID NO: 52). [00177] SEQ ID NO: 52:
  • MS4 polypeptide sequence in GBS strain M732 is publicly available and has Accession No. CAC09078 in Genbank. [00179] SEQ ID NO: 54
  • MS4 polynucleotide sequence (SEQ ID NO: 53) encoding the MS4 polypeptide in
  • GBS strain M732 is publicly available and has AccessionNo. AX026599 in Genbank. [00181] SEQ ID NO: 53
  • a serotypic variant of the MS4 polypeptide is found in GBS strain A909 and has locus
  • MSIl polypeptide sequence (SEQ ID NO: 57) in GBS strain M732 is publicly available and has Accession No. CAC09079 in Genbank. [00185] SEQ ID NO: 57
  • MSl1 polynucleotide sequence (SEQ ID NO: 56) encoding the MSl1 polypeptide in
  • GBS strain M732 is publicly available andhas Accession No. AX026601 in Genbank. [00187] SEQ ID NO: 56
  • a serotypic variant ofthe MS4 polypeptide is found in GBS strain A909 and has locus tagno. SAK l788 (SEQ ID NO: 58). [00189] SEQ ID NO: 58:
  • MS16 polypeptide sequence I (SEQ ID NO: 60 ⁇ in GBS strain M732 is publicly available and has Accession No. CAC09080 in Genbank. [00191] SEQ ID NO: 60
  • MS16 polynucleotide sequence I (SEQ ID NO: 59) encoding the MS16 polypeptide in GBS strain M732 is publicly available andhas AccessionNo. AX026603 in Genbank. [00193] SEQ ID NO: 59
  • MS16 polypeptide sequence II (SEQ ID NO: 62) in GBS strain M732 is publicly available and has Accession No. CAC09081 in Genbank.
  • MS16 polynucleotide sequence II (SEQ ID NO: 61) encoding the MS16 polypeptide in GBS strain M732 is publicly available andhas Accession No. AX026605 in Genbank. [00197] SEQ ID NO: 61
  • a serotypic variant ofthe MS16 polypeptide is found in GBS strain A909 and has locus tag no. SAK_0475 (SEQ ID NO: 63). [00199] SEQ ID NO: 63:
  • MS14 polypeptide sequence (SEQ ID NO: 65) in GBS strain M732 is publicly available and has Accession No. CAC09082 in Genbank. [00201] SEQ ID NO: 65
  • MS14 polynucleotide sequence (SEQ ID NO: 64) encoding the MS14 polypeptide in
  • GBS strain M732 is publicly available and has Accession No. AX026607 in Genbank. [00203] SEQ ID NO: 64
  • a serotypic variant ofthe MS14 polypeptide is found in GBS strain A909 and has locus tag no. SAK_1267 (SEQ ID NO: 66). [00205] SEQ ID NO: 66:
  • MSlO polypeptide sequence (SEQ ID NO: 68) in GBS strain M732 is publicly available and has Accession No. CAC09083 in Genbank.
  • MSlO NP GAP; ME:NAP
  • SEQ ID NO: 67 The MSlO polypeptide in GBS strain M732 is publicly available and has Accession No. AX026609 in Genbank.
  • a serotypic variant of the MSlO polypeptide is found in GBS strain A909 and has locus tag no. SAK_0947 (SEQ ID NO: 69). [00211] SEQ ID NO: 69:
  • a combination of two or more polypeptides induces an immune response.
  • the immune response may have additive effect.
  • a combination of two or more polypeptides or polynucleotides may induce synergistic immune response.
  • Polypeptides, and fragments, derivatives, analogs, or variants thereof of the present invention can be antigenic and immunogenic fragment of the GBS polypeptides, which may also be used to prevent or treat, i.e., cure, ameliorate, lessen the severity of, or prevent or reduce contagion of infectious disease caused by GBS, or other species as disclosed herein.
  • antigens and its related term “antigenic” as used herein and in the claims refer to a substance that binds specifically to an antibody or T-cell receptor. In some embodiments the antigens are immunogenic.
  • immunogenic refers to an antigen capable of inducing an immune response directed against itself when administered to a subject.
  • Peptides or polypeptides e.g., immunogenic epitopes, capable of eliciting an immunogenic response are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins nor to the ammo or carboxyl terminals.
  • Polypeptides that are extremely hydrophobic, and those of six or fewer residues generally are ineffective at inducing antibodies, but may still bind antibodies raised against larger portions of the polypeptide; longer peptides, especially those containing proline residues, usually are effective (Sutcliffe, J. G., et al., Science 219:660-666 (1983)).
  • antigenic epitopes or antigenic fragments can contain a sequence of at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, or at least 450 contained within the amino acid sequence of the polypeptides of the invention.
  • Antigenic as well as immunogenic epitopes may be linear, i.e., be comprised of contiguous amino acids in a polypeptide, or may be three dimensional, i.e., where an epitope is comprised of non-contiguous amino acids which come together due to the secondary or tertiary structure of the polypeptide, thereby forming an epitope.
  • a fragment comprising an antigenic and immunogenic polypeptide of the present invention can be predicted based on antigenicity of the GBS polypeptides described herein.
  • Such fragments can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, N.J.
  • linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports.
  • Antigenic regions of proteins can also be identified using standard antigenicity and hydropathy plots, such as those calculated using, e.g., the Omiga version 2.0 software program available from the Oxford Molecular Group.
  • This computer program employs the Hopp/Woods method, Hopp et al., Proc. Natl. Acad. Sci USA (1981) 78:3824-3828 for determining antigenicity profiles, parker antigenicity method, Parker et al., Biochem. (1986), 25, 5425-5432; Protrusion Index antigenicity, Thornton et al., EMBO Journal (1986) 5: 409-413; and Welling antigenicity, FEBS Lett. (1985) 188:215-218.
  • Figure 1 shows the Hope/Woods antigenicity profile of the GBS polypeptides described herein.
  • Other techniques e.g., the Kyte-Doolittle technique, Kyte et al., J. MoI. Biol. (1982) 157:105-132, may be used to measure hydropathy of the GBS polypeptides.
  • an antigenic or immunogenic fragment of the Phol-13 polypeptide may be selected from the group consisting of amino acids 1- 21, 28-34, 51-56, 27-41, 55-93, 43-53, 94-116, 119-146, 119-146, 138-153, 154-180, 146-182, 159-166, and 168-175 of SEQ E) NO: 2.
  • an antigenic or immunogenic Phol-13 polypeptide fragment may be amino acids 21-59, 132-181, 101-181, or 1- 181 of SEQ ID NO: 2.
  • An antigenic or immunogenic polypeptide fragment of the Phol-14 polypeptide may be selected from the group consisting of amino acids 25-31, 19-31, or 1-45 of SEQ ID NO: 5.
  • An antigenic or immunogenic polypeptide fragment of the Phol-5 polypeptide may be selected from the group consisting of amino acids 1-14, 1-22, 43-115, 45-87, 127-220, 178-192, 145-157, and 145-163 or SEQ ID NO: 8.
  • an antigenic or immunogenic Phol-5 polypeptide fragment may be amino acids 43-115, 139-192, or 43-192 of SEQ ID NO: 8.
  • An antigenic or immunogenic polypeptide fragment of the Pho3-3 polypeptide may be selected from the group consisting of amino acids 1-18, 18-42, 58-68, 47-53, 69-110, and 165-197 of SEQ ID NO: 11. In preferred embodiments, an antigenic or immunogenic Pho3-3 polypeptide fragment may be amino acids 1-88, 1-110, or 165-197 of SEQ ID NO: 11. [00221] An antigenic or immunogenic polypeptide fragment of the Pho2-10 polypeptide may be selected from the group consisting of amino acids 13-19, 37-61, 80-98, 1-24, 85-101, 121-133, 127-143, 130-157, 64-84 and 175-197 of SEQ ID NO: 14. In preferred embodiments, an antigenic or immunogenic Pho2-10 polypeptide fragment may be amino acids 1-59, 84-149, or 1- 149 of SEQ ID NO: 14 or SEQ ID NO: 15.
  • An antigenic or immunogenic polypeptide fragment of the Pho2-15 polypeptide may be amino acids 29-95, 1-95, 68-79 or 29-125 of SEQ DD NO: 18. In preferred embodiments, an antigenic or immunogenic Pho2-15 polypeptide fragment may be amino acids 29-95, 1-95, or 29- 125 of SEQ ID NO: 18.
  • An antigenic or immunogenic polypeptide fragment of the Pho2-2 polypeptide may be selected from the group consisting of amino acids 70-78, 106-147, 168-200, 273-290, and 301- 350 of SEQ ID NO:21.
  • an antigenic or immunogenic Pho2-2 polypeptide fragment may include amino acids 1-77, 106-225, 272-360, or 106-360 of SEQ ID NO:21.
  • An antigenic or immunogenic polypeptide fragment of the Pho3-14 polypeptide may be selected from the group consisting of amino acids 1-36, 43-65, 65-91, and 91-122 of SEQ ID NO: 24.
  • an antigenic or immunogenic Pho3-14 polypeptide fragment may be amino acids 43-84, 1-84, 88-122, or 38-122 of SEQ BD NO: 24.
  • An antigenic or immunogenic polypeptide fragment of the Pho3-17 polypeptide may be selected from the group consisting of amino acids 27-40, 29-62, 29-84, 101-122, 97-189, 110- 140, 131-149, 154-189, and 155-170 of SEQ ID NO: 27.
  • an antigenic or immunogenic Pho3-17 polypeptide fragment may be amino acids 29-79, 101-189, or 29-189 of SEQ ID NO: 27.
  • An antigenic or immunogenic polypeptide fragment of the Pho3-18 polypeptide may be selected from the group consisting of amino acids 23-45, 80-105, 105-142, 146-182, 190-217, 269-278, and 302-325 of SEQ ID NO: 30.
  • an antigenic or immunogenic Pho3-18 polypeptide fragment may be amino acids 79-182, 79-217, 23-217, or 23- 278 of SEQ ID NO: 30.
  • An antigenic or immunogenic polypeptide fragment of the Pho3-1 polypeptide may be selected from the group consisting of amino acids 24-39, 71-99, 113-150, 150-192, and 113-192 of SEQ DD NO: 33.
  • an antigenic or immunogenic Pho3-1 polypeptide fragment may be amino acids 113-192, 71-192, or 24-192 of SEQ DD NO: 33.
  • An antigenic or immunogenic polypeptide fragment of the Pho3-21 polypeptide may be selected from the group consisting of amino acids 25-40, 56-80, 98-107, 133-142, 153-172, and 181-202 of SEQ DD NO: 36. In preferred embodiments, an antigenic or immunogenic Pho3-21 polypeptide fragment may be amino acids 25-88, 132-202, 25-172, or 25-202 of SEQ DD NO: 36. [00229] An antigenic or immunogenic polypeptide fragment of the Pho3-22 polypeptide may be selected from the group consisting of amino acids 27-60, 60-94, and 27-94 of SEQ ID NO: 39. In preferred embodiments, an antigenic or immunogenic Pho3-22 polypeptide fragment may be amino acids 27-94 of SEQ ID NO: 39.
  • An antigenic or immunogenic polypeptide fragment of the Pho3-23 polypeptide may be selected from the group consisting of amino acids 76-87, 111 -180, 111 -234, 72-234, or 40-335 of SEQ ID NO: 42.
  • an antigenic or immunogenic Pho3-23 polypeptide fragment may be amino acids 111-180, 111-234, 72-234, or 40-335 of SEQ ID NO: 42.
  • An antigenic or immunogenic polypeptide fragment of the Pho3-24 polypeptide may be selected from the group consisting of amino acids 159-180, 260-277, 346-370, and 300-310 of SEQ ID NO: 45.
  • an antigenic or immunogenic Pho3-24 polypeptide fragment may be amino acids 98-180, 259-370, or 98-370 of SEQ ID NO: 45.
  • An antigenic or immunogenic polypeptide fragment of the Pho3-29 polypeptide may be amino acids 21-33 of SEQ ID NO: 48.
  • An antigenic or immunogenic polypeptide fragment of the Pho3-50 polypeptide may be selected from the group consisting of amino acids 1-20, 28-37, 79-95, 102-112, 140-155, 192- 202, and 202-217 of SEQ ID NO: 51.
  • an antigenic or immunogenic Pho3-50 polypeptide fragment may be amino acids 78-154, 78-217, or 1-154 of SEQ ID NO: 51.
  • An antigenic or immunogenic polypeptide fragment of the MS4 polypeptide may be selected from the group consisting of amino acids 1-44, 51-63, 80-102, 102-117, 191 -205, 205- 225, 231-253, and 281-321 of SEQ ID NO: 54.
  • an antigenic or immunogenic MS4 polypeptide fragment may be amino acids 190-261, 190-321 or 1-118 of SEQ ID NO: 54.
  • An antigenic or immunogenic polypeptide fragment of the MS 11 polypeptide may be selected from the group consisting of amino acids 1-24, 24-35, 56-79, 112-140, 91-111, 182-202, 205-220, 240-270, 274-295, and 297-310 of SEQ ID NO: 57.
  • an antigenic or immunogenic MSI l polypeptide fragment may be amino acids 1-139, 184-311, or 184-398 of SEQ ID NO: 57.
  • An antigenic or immunogenic polypeptide fragment of the MS 16 polypeptide may be selected from the group consisting of amino acids 48-77, 101-116, 128-145, and 157-172 of SEQ ID NO: 60 and amino acids 1-30 and 75-105 of SEQ ID NO: 62.
  • an antigenic or immunogenic MS 16 polypeptide fragment may be amino acids 24-77, 101-172, or 24-172 of SEQ ID NO: 60 or SEQ ID NO: 62.
  • An antigenic or immunogenic polypeptide fragment of the MS 14 polypeptide may be selected from the group consisting of amino acids 1-18, 32-45, 141-154, 154-162, 162-180, and 241-268 of SEQ ID NO: 65.
  • an antigenic or immunogenic MS14 polypeptide fragment may be amino acids 1-95, 141-181, or 141-268 of SEQ ID NO: 65.
  • An antigenic or immunogenic polypeptide fragment of the MSlO polypeptide may be selected from the group consisting of amino acids 31-50, 78-89, 105-138, 212-220, 255-270, 285- 315, 330-360, 382-400, and 405-445 of SEQ ID NO: 68.
  • an antigenic or immunogenic MSlO polypeptide fragment may be amino acids 1-138, 285-363, 210-363, 210- 444, or 285-444 of SEQ ID NO: 68.
  • the beginning and ending residues of the antigenic or immunogenic polypeptide fragment may vary depending upon the computer modeling program used or the method used for determining the domains.
  • Isolated antigenic and immunogenic polypeptides of the present invention in addition to those encoded by polynucleotides of the invention, may be provided as a recombinant protein, a purified subunit, a viral vector expressing the protein, or may be provided in the form of an inactivated GBS vaccine, e.g., a live-attenuated virus vaccine, a heat-killed virus vaccine, etc.
  • an inactivated GBS vaccine e.g., a live-attenuated virus vaccine, a heat-killed virus vaccine, etc.
  • Production of the polypeptides of the present invention can be achieved by culturing the host cells, expressing the polynucleotides of the present invention, and recovering the polypeptides. Determining conditions for culturing the host cells and expressing the polynucleotide are generally specific to the host cell and the expression system and are within the knowledge • of one of skill in the art. Likewise, appropriate methods for recovering the polypeptide of interest are known to those in the art, and include, but are not limited to. chromatography, filtration, precipitation, or centrifugation.
  • polypeptides of the present invention are suitable for using as a vaccine composition as the polypeptides have low levels of sequence identity with human proteins.
  • the compositions comprising a combination of the polypeptides can elicit a strong immune response without producing an immune response against natural human polypeptides, thereby improving the safety profile of the combinations.
  • Table 3 shows the polypeptides of the invention and the levels of homology between the polypeptides and other polypeptides found in humans.
  • GBS polypeptides are known from different serotypes, different strains, and different species.
  • sequence identity between the GBS polypeptides and the corresponding polypeptide sequences from- different serotypes or strains or different species are publicly available as shown in Table 4.
  • Table 5 shows the polypeptide sequence identities between the GBS A909 and different species, serotypes, and strains.
  • Serotypic variation of GBS polypeptides is lower than the variation among species.
  • Serotypic variants are therefore expected to be immunologically cross-reactive.
  • the present invention thus includes GBS polypeptides found in other Streptococcus spp, e.g., Streptococcus agalactiae serotypes such as, but not limited to, Ia, Ib, Ia/c, II, III, IV, V, VI, VII, and VIII, or Streptococcus agalactiae, Streptococcus bovis, Streptococcus equi, Streptococcus gordonii, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus ratti, Streptococcus salivarius, Streptococcus suis, or Streptococcus thermophilus or fragments thereof.
  • Streptococcus spp e.
  • the present invention is directed to an isolated first polypeptide and an isolated second polypeptide, wherein each of the first polypeptide and the second polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (a) a Phol-13 polypeptide, which is selected from the group consisting of (i) SEQ ID NO: 2; (ii) amino acids 1- 59 of SEQ ID NO: 2; (iii) amino acids 132-181 of SEQ ID NO: 2; (iv) amino acids 101-181 of SEQ ID NO: 2; and (v) amino acids 1-181 of SEQ ID NO: 2; (b) a Phol-14 polypeptide, which is selected from the group consisting of (i) SEQ ID NO: 5 and (ii) amino acids 1-45 of SEQ ID NO: 5;
  • the first polypeptide and the second polypeptide induces an immune response against GBS.
  • the immune response prevents, treats, or ameliorates a condition or disorder associated with Group B Streptococcal infection in the animal.
  • the first polypeptide and the second polypeptide further comprises an isolated third polypeptide.
  • the third polypeptide may be an antigenic or immunogenic polypeptide, e.g., a polypeptide derived from a bacterium, a virus, a fungus, or a protozoan.
  • the antigenic or immunogenic polypeptide may be derived from Group B Streptococcus.
  • the third polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (a) a Phol-13 polypeptide, which is selected from the group consisting of (i) SEQ E) NO: 2; (ii) amino acids 1-59 of SEQ E) NO: 2; (iii) amino acids 132-181 of SEQ E ) NO: 2; (iv) amino acids 101-181 of SEQ E ) NO: 2; and (v) amino acids 1-181 of SEQ ID NO: 2; (b) a Phol-14 polypeptide, which is selected from the group consisting of (i) SEQ ID NO: 5 and (ii) amino acids 1-45 of SEQ ID NO: 5;(c) a Phol-5 polypeptide, which is selected from the group consisting of (i) SEQ ID NO: 8; (ii) amino acids 43-115 of SEQ ID NO:
  • the first polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ DD NO: 33; (ii) amino acids 113-192 of SEQ DD NO: 33; (iii) amino acids 71-192 of SEQ DD NO: 33; and (iv) amino acids 24-192 of SEQ DD NO: 33; and the second polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ DD NO: 21; (ii) amino acids 1-77 of SEQ DD NO: 21; (iii) amino acids 106-225 of SEQ DD NO: 21; (iv) amino acids 272-360 of SEQ DD NO: 21
  • the first polypeptide comprises an amino acid sequence at least 80%, 85%,
  • the second polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the reference amino acid sequence selected from the group consisting of: (i) SEQ DD NO: 68, (ii) amino acids 1-138 of SEQ DD NO: 68; (iii) amino acids 285-363 of SEQ DD NO: 68; (iv) amino acids 210-363 of SEQ DD NO: 68; (v) amino acids 210-444
  • the present invention includes a combination of an isolated first polypeptide, an isolated second polypeptide, and an isolated third polypeptide, wherein the first polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ DD NO: 33; (ii) amino acids 113-192 of SEQ DD NO: 33; (iii) amino acids 71-192 of SEQ DD NO: 33; and (iv) amino acids 24-192 of SEQ DD NO: 33, the second polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ DD NO: 21; (ii) amino acids 1-77 of SEQ DD NO: 21; (iii) amino acids 106-225 of SEQ ID
  • an antibody raised against the first and second polypeptides of the present invention may show cross reactivity against the corresponding polypeptides found in multiple GBS strains or serotypes.
  • the first and second polypeptide used in the present invention may further show cross protection against different GBS strains or serotypes.
  • a first polypeptide comprising SEQ DD NO: 33 and a second polypeptide comprising SEQ DD NO: 68 may show protection against GBS strain M732 as well as GBS strain GBS strain A909 (serotype Ia/c).
  • the present invention also includes a combination of two or more polypeptides wherein the first polypeptides and second polypeptides are from different GBS serotypes.
  • the present invention may include an isolated first polypeptide comprising SEQ DD NO: 33 (Pho3- 1) found in GBS M732 (serotype III) and a second polypeptide comprising SEQ ID NO: 69 (MS 10 corresponding polypeptide) found in GBS A909 (serotype Ia).
  • the first polypeptide and second polypeptide may therefore show protection against both GBS A909 and M732, when administered to a host in need thereof.
  • the first and second polypeptide may also show protection against GBS serotypes Ib, Ib/c, II, IV, V, VI, VII, and/or VIII. Likewise, other combinations of the GBS polypeptides from different serotypes are also possible.
  • the present invention is directed to at least two different GBS polypeptides, wherein the polypeptides further comprising a heterologous polypeptide.
  • the heterologous polypeptide can, in some embodiments, be fused to the GBS polypeptide.
  • the heterologous polypeptide can be translated from various heterologous nucleic acids.
  • heterologous polypeptides can be used, and can be selected from the group consisting of an N- or C-terminal peptide imparting stabilization, secretion, or simplified purification, i.e., His-tag, ubiquitin tag, NusA tag, chitin binding domain, ompT, ompA, pelB, DsbA, DsbC, c-myc, KSI, polyaspartic acid, (Ala-Trp-Trp-Pro)n, polyphenylalanine, polycysteine, polyarginine, B-tag, HSB-tag, green fluorescent protein (GFP), hemagglutinin influenza virus (HAI), calmodulin binding protein (CBP), galactose-binding protein, maltose binding protein (MBP), cellulose binding domains (CBD's), dihydrofolate reductase (DHFR), glutathione-S-transferase (GST), strepto
  • heterologous polypeptides can further include any pre- and/or pro- sequences that facilitate the transport, translocations, processing and/or purification of the GBS polypeptides from a host cell or any useful immunogenic sequence, including but not limited to sequences that encode a T-cell epitope of a microbial pathogen, or other immunogenic proteins and/or epitopes.
  • heterologous polypeptides may include other GBS proteins (either native proteins or variants, fragments, or derivatives thereof.)
  • the heterologous polypeptide may comprise one or more polypeptides from different GBS serotypes or strains. Accordingly, the at least two GBS polypeptides can induce an immune response against various serotypes of GBS.
  • the heterologous polypeptide may be from other organisms.
  • the polypeptide of the present invention can exist as a homopolymer, comprising multiple copies of the same polypeptide.
  • these polypeptides fused with a heterologous polypeptide can include a peptide linker sequence joining sequences that comprise two or more epitopes.
  • Suitable peptide linker sequences may be chosen based on their ability to adopt a flexible, extended conformation, or a secondary structure that could interact with joined epitopes, or based on their ability to increase overall solubility of the fusion polypeptide, or based on their lack of electrostatic or water-interaction effects that influence joined epitopes.
  • Peptide and polypeptide sequences defined herein are represented by one-letter symbols for amino acid residues as follows: A (alanine); R (arginine); N (asparagine); D (aspartic acid); C (cysteine); Q (glutamine); E (glutamic acid); G (glycine); H (histidine); I (isoleucine); L (leucine); K (lysine); M (methionine); F (phenylalanine); P (proline); S (serine); T (threonine); W (tryptophan); Y (tyrosine); and V (valine).
  • the present invention also include an isolated first polynucleotide and an isolated second polynucleotide, wherein the first polynucleotide and the second polynucleotide encode the GBS polypeptides, fragments, derivatives, analogs, or variants thereof described herein.
  • Polynucleotides or nucleic acid sequences defined herein are represented by one-letter symbols for the bases as follows: A (adenine) C (cytosine) G (guanine) T (thymine) U (uracil) M (A or C) R (A or G) W (A or T/U); S(C or G); Y (C or T/U); K (G or T/U); V (A or C or G; not T/U) ; H (A or C or T/U; not G); D (A or G or T/U; not C); B (C or G or T/U; not A); N (A or C or G or T/U) or (unknown).
  • an isolated first polynucleotide used in the present invention encodes a first polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 33; (ii) amino acids 113-192 of SEQ ED NO: 33; (iii) amino acids 71-192 of SEQ ID NO: 33; and (iv) amino acids 24-192 of SEQ ID NO: 33; and an isolated second polynucleotide used in the present invention encodes a second polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of (i) SEQ ED NO: 21; (ii) amino acids 1-77 of SEQ ED NO: 21; (iii) amino acids 106-225
  • an isolated first polynucleotide encodes a first polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ED NO: 33;'(ii) amino acids 113-192 of SEQ ED NO: 33; (iii) amino acids 71-192 of SEQ ED NO: 33; and (iv) amino acids 24-192 of SEQ ED NO: 33; and an isolated second polynucleotide encodes a second polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 68, (ii) amino acids 1-138 of SEQ ID NO: 68; (iii) amino acids 285-363 of SEQ
  • an isolated first polynucleotide encodes a first polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 21; (ii) amino acids 1-77 of SEQ ID NO: 21; (iii) amino acids 106-225 of SEQ ID NO:21; (iv) amino acids 272-360 of SEQ ID NO:21; and (v) amino acids 106-360 of SEQ ID NO:21; and an isolated second polynucleotide encodes a second polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 68, (ii) amino acids 1-138 of SEQ ID NO: 68; (iii)
  • the present invention is directed to a polynucleotide further comprising a heterologous nucleic acid.
  • the heterologous nucleic acid can, in some embodiments, encode a heterologous polypeptide fused to the polypeptide.
  • the heterologous nucleic acid may comprise a promoter operably linked to the first, second, or third polynucleotide.
  • the heterologous nucleic acid may encode a third polypeptide.
  • the third polypeptide may be an antigenic or immunogenic polypeptide.
  • an antigenic or immunogenic polypeptide may be derived from a bacterium, a virus, a fungus, or a protozoan.
  • a heterologous nucleic acid may encode a polypeptide derived from Group B Streptococcus.
  • the polypeptide derived from GBS may be any GBS polypeptides, fragments, derivatives, or variants described herein.
  • GBS polypeptide variants are also included within the scope of the invention.
  • Modifications of nucleic acids encoding the GBS polypeptides can readily be accomplished by those skilled in the art, for example, by oligonucleotide-directed site-specific mutagenesis of a polynucleotide coding for a GBS polypeptide.
  • modified polypeptide can be encoded by a codon optimized nucleotide sequence.
  • Such modifications impart one or more amino acid substitutions, insertions, deletions, and/or modifications to expressed GBS polypeptides including fragments, variants, and derivatives.
  • modifications may enhance the immunogenicity of the GBS antigens, for example, by increasing cellular immune responses compared with unmodified polypeptides. Such modification may enhance solubility of the polypeptides. Alternatively, such modifications may have no effect.
  • the polynucleotide encoding the GBS polypeptide may be modified by introduction, deletion or modification of particular cleavage sites for proteolytic enzymes active in antigen presenting cells, to enhance immune responses to particular epitopes.
  • various nucleic acid coding regions will encode the same polypeptide due to the redundancy of the genetic code.
  • Deviations in the nucleotide sequence that comprise the codons encoding the amino acids of any polypeptide chain allow for variations in the sequence coding for the gene. Since each codon consists of three nucleotides, and the nucleotides comprising DNA are restricted to four specific bases, there are 64 possible combinations of nucleotides, 61 of which encode amino acids (the remaining three codons encode signals ending translation). The "genetic code” which shows which codons encode which amino acids is reproduced herein as Table 6. As a result, many amino acids are designated by more than one codon.
  • amino acids alanine and proline are coded for, by four triplets, serine and arginine by six, whereas tryptophan and methionine are coded by just one triplet.
  • This degeneracy allows for DNA base composition to vary over a wide range without altering the amino acid sequence of the polypeptides encoded by the DNA.
  • Codon preference or codon bias differences in codon usage between organisms, is afforded by degeneracy of the genetic code, and is well documented among many organisms. Codon bias often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, inter alia, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules.
  • mRNA messenger RNA
  • tRNA transfer RNA
  • the predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization.
  • Codon usage tables are readily available, for example, at the "Codon Usage Database” available at www.kazusa.or.jp/codon/ (visited August 6, 2007), and these tables can be adapted in a number of ways. See Nakamura, Y., et al, "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28:292 (2000).
  • codon usage tables By utilizing the codon usage tables, one of ordinary skill in the art can apply the frequencies to any given polypeptide sequence, and produce a nucleic acid fragment comprising a codon-optimized coding region which encodes the polypeptide, but which uses codons optimal for a given species.
  • the coding region is codon-optimized for expression in E.coli.
  • Randomly assigning codons at an optimized frequency to encode a given polypeptide sequence can be done manually by calculating codon frequencies for each amino acid, and then assigning the codons to the polypeptide sequence randomly.
  • various algorithms and computer software programs are readily available to those of ordinary skill in the art. For example, the "EditSeq" function in the Lasergene Package, available from DNAstar, Inc., Madison, WI, the backtranslation function in the VectorNTI Suite, available from InforMax, Inc., Bethesda, MD, and the "backtranslate" function in the GCG ⁇ Wisconsin Package, available from Accelrys, Inc., San Diego, CA. Constructing a rudimentary algorithm to assign codons based on a given frequency can also easily be accomplished with basic mathematical functions by one of ordinary skill.
  • Codon placement in a polynucleotide at an optimized frequency to encode a given polypeptide sequence can also be done in a directed manner.
  • a codon may be assigned to a particular amino acid so as to create or destroy a restriction enzyme cleavage site. Creation or destruction of restriction enzyme sites may facilitate DNA manipulation by assisting with cloning or forming identifying markers.
  • a codon may be assigned, to a particular amino acid so as to achieve a desired secondary structure of the polynucleotide.
  • an entire coding region encoding a polypeptide sequence, or fragment, variant, or derivative thereof can be codon optimized by any of the methods described herein or by other methods.
  • Various desired fragments, variants or derivatives may be designed, and each can then be codon-optimized individually.
  • partially codon-optimized coding regions of the present invention can be designed and constructed.
  • the invention includes a nucleic acid fragment of a codon-optimized coding region encoding a polypeptide in which at least about 1%, 2%, 3,% 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the codon positions have been codon-optimized for a given species.
  • the partially codon optimized coding regions contain a codon that is preferentially used in the genes of a desired species, e.g., E.coli, in place of a codon that is normally used in the native nucleic acid sequence.
  • the present invention further provides a vector or more than one vectors comprising one or more polynucleotides encoding the GBS polypeptides, fragments, derivatives, or variants thereof.
  • a vector which comprises at least two nucleic acid sequences encoding the GBS polypeptides or fragments, variants, derivatives, or analogs thereof described herein.
  • the at least two nucleic acid sequence may comprises an isolated first nucleic acid sequence and an isolated second nucleic acid sequence, which are located on one expression vector.
  • the present invention is further directed to at least two vectors, each of which comprises a nucleic acid fragment encoding a GBS polypeptide.
  • the at least two vectors can be identical or different or a combination thereof.
  • the nucleic acid fragment may be a fragment of a codon-optimized coding region operably encoding any GBS polypeptides described herein.
  • Additional GBS-derived coding or non-coding regions may also be included on the vector, e.g., a plasmid, or on a separate vector, and expressed, either using native GBS codons or codons optimized for expression in the host in which the polypeptide is being expressed.
  • a vector is delivered to a host, e.g., to a bacterial, plant or eukaryotic cell, or alternatively, in vivo to a tissue of the animal to be treated or immunized, the transcriptional unit will thus express the encoded gene product.
  • the level of expression of the gene product will depend to a significant extent on the strength of the associated promoter and the presence and activation of an associated enhancer element, as well as the optimization of the coding region.
  • vector refers to any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell.
  • Vectors may be DNA or RNA.
  • Vectors include, but are not limited to, plasmids, phage, phagemids, bacterial genomes, and virus genomes and virus-like particles.
  • a cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell.
  • replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis.
  • phage replication may occur actively during a lytic phase or passively during a lysogenic phase.
  • Certain vectors are capable of autonomous replication in a host cell into which they are introduced. Other vectors are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • plasmid refers to a circular, double-stranded construct made up of genetic material (i.e., nucleic acids), wherein the genetic material is extrachromosomal and replicates autonomously.
  • a polynucleotide of the present invention may be in a circular or linearized plasmid or vector, or other linear DNA which may also be non-infectious and nonintegrating (i.e., does not integrate into the genome of host cells).
  • a variety of host-expression vector systems may be utilized to express the polypeptides of the present invention.
  • expression vector refers to a vector that is capable of expressing the polypeptide of the present invention, i.e., the vector sequence contains the regulatory sequences required for polypeptide expression such as promoters, ribosome binding sites, etc.
  • expression refers to the biological production of a product encoded by a coding sequence. In most cases a DNA sequence, including the coding sequence, is transcribed to form a messenger-RNA (mRNA). The messenger-RNA is then translated to form a polypeptide product which has a relevant biological activity. Also, the process of expression may involve further processing steps to the RNA product of transcription, such as splicing to remove introns, and/or post-translational processing of a polypeptide product.
  • mRNA messenger-RNA
  • Vector-host systems include, but are not limited to, systems such as bacterial, mammalian, yeast, insect or plant cell systems. either in vivo, e.g., in an animal or in vitro, e.g., in mammalian cell cultures. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.
  • Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention as described above.
  • one aspect of the invention is directed to a host cell comprising a vector which contains a polynucleotide of the present invention.
  • the engineered host cell can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the polynucleotides.
  • the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • transfect refers to any procedure whereby eukaryotic cells are induced to accept and incorporate into their genome isolated DNA, including but not limited to DNA in the form of a plasmid.
  • transform refers to any procedure whereby bacterial cells are induced to accept and incorporate into their genome isolated DNA, including but not limited to DNA in the form of a plasmid.
  • Bacterial host-expression vector systems include, but are not limited to, a prokaryote
  • PFENEXTM PFENEX TM (Dowpharma)
  • Streptomyces sp. or Staphylococcus sp.
  • PFENEXTM PFENEX TM (Dowpharma)
  • Streptomyces sp. or Staphylococcus sp.
  • PFENEXTM PFENEXTM
  • the PFENEXTM system is used.
  • the PFENEXTM expression system utilizes P. fluorescens biovar I, designated MBlOl, and compatible plasmids.
  • the plasmids used with P. fluorescens use the tac promoter system regulated by the Lad protein via IPTG induction.
  • the bacterial host can have an auxotrophic chromosomal deletion, e.g., pyrF, in which the deletion is complemented by the vector, to alleviate the need for antibiotic-resistance genes.
  • auxotrophic chromosomal deletion e.g., pyrF
  • a large number of suitable vectors are known to those of skill in the art, and are commercially available.
  • the following bacterial vectors are provided by way of example: pET, pET28, pBAD, pTrcHIS, pBR322, pQE70, pQE60, pQE-9 (Qiagen), phagescript, psiX174, pBluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540, pBR322, pPSIO, RSFlOlO, pRIT5 (Pharmacia); pCR (Invitrogen); pLex (Invitrogen), and pUC plasmid derivatives.
  • the expression vector comprises the plasmid pLex.
  • the pLex plasmid comprises a multiple cloning site that is tightly regulated by a tryptophan-inducible expression system utilizing the strong P L promoter from bacteriophage lambda, and the cl repressor protein. This pLex expression vector is especially useful for the expression of potentially toxic proteins in E. coli.
  • the lambda promoter provides high-level expression of recombinant proteins.
  • a GBS polypeptide antigen can be recombinantly expressed directly in a carrier organism, or virus, all or part of which is subsequently incorporated in a vaccine composition, as described in Eko, et al, Immunol., 173:3375-3382, 2004, which is expressly incorporated by reference herein.
  • GBS polypeptide vaccine antigens can be purified from infected-host cell culture.
  • a suitable expression vector contains regulatory sequences which can be operably joined to an inserted nucleotide sequence encoding a GBS polypeptide vaccine antigen.
  • regulatory sequences means nucleotide sequences which are necessary for or conducive to the transcription of an inserted sequence coding a GBS vaccine antigen by a host cell and/or which are necessary for or conducive to the translation by a host cell of the resulting transcript into the desired GBS polypeptide.
  • Regulatory sequences include, but are not limited to, 5 1 sequences such as operators, promoters and ribosome binding sequences, and 3' sequences such as polyadenylation signals. Regulatory sequences may also include enhancer sequences or upstream activator sequences.
  • bacterial vectors will include origins of replication and selectable markers, e.g., the ampicillin, tetracycline, kanamycin, resistance genes of E. coli, permitting transformation of the host cell and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence.
  • promoters include, but are not limited to, the T7 promoter, lambda ( ⁇ ) promoter, T5 promoter, and lac promoter, or promoters derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), acid phosphatase, or heat shock proteins, among others.
  • the polynucleotide of the invention is cloned downstream of the promoter, often in a polylinker region.
  • This plasmid is transformed into an appropriate bacterial strain, and DNA is prepared using standard techniques.
  • the orientation and DNA sequence of the polynucleotide as well as all other elements included in the vector, are confirmed using restriction mapping, DNA sequence analysis, and/or PCR analysis.
  • Bacterial cells harboring the correct plasmid can be stored as cell banks.
  • Examples of mammalian host-expression systems include cell lines capable of expressing a compatible vector, for example, the COS, C127, 3T3, CHO, HeLa and BHK cell lines.
  • suitable expression vectors include pWLNEO, pSV2CAT, pOG44, pXTl, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia), p75.6 (Valentis), pCEP (Invitrogen), pCEI (Epimmune), pZERO, P Trc99A, pUC19, pUC18, pKK223-3, pEXl, pCAL, pET, pSPUTK, pTrxFus, pFastBac, pThioHis, pTrcHis, and pLex, pET-17b, pET-1 Ia, pET-24a-d(+
  • mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences.
  • promoters may also be derived from viral sources, such as, e.g., human cytomegalovirus (CMV-EE promoter), herpes simplex virus type-1 (HSV TK promoter), the adenovirus late promoter; and the vaccinia virus 7.5K promoter, or can be derived from the genome of mammalian cells (e.g., metallothionein promoter).
  • Nucleic acid sequences derived from the SV40 splice and polyadenylation sites can be used to provide the required nontranscribed genetic elements.
  • a variety of transcription control regions are known to those skilled in the art. These include, without limitation, transcription control regions which function in animal cells, such as, but not limited to, promoter and enhancer segments from cytomegaloviruses (the immediate early promoter, in conjunction with intron-A), simian virus 40 (the early promoter), and retroviruses (such as Rous sarcoma virus).
  • Other transcription control regions include those derived from animal genes such as actin, heat shock protein, bovine growth hormone and rabbit ⁇ -globin, as well as other sequences capable of controlling gene expression in eukaryotic cells.
  • transcription control regions include tissue-specific promoters and enhancers as well as lymphokine-inducible promoters (e.g., promoters inducible by interferons or interleukins).
  • tissue-specific promoters and enhancers as well as lymphokine-inducible promoters (e.g., promoters inducible by interferons or interleukins).
  • lymphokine-inducible promoters e.g., promoters inducible by interferons or interleukins.
  • translation control elements include, but are not limited to ribosome binding sites, translation initiation and termination codons, elements from picornaviruses (particularly an internal ribosome entry site, or IRES, also referred to as a CITE sequence).
  • Yeast host-expression systems include a yeast host (e.g., Saccharomyces, Pichia,
  • Suitable yeast expression vectors are known to those in the art and include, but are not limited to, e.g., pAL19, paR3, pBGl, pDBlet, pDB248X, pEA500, pFL20, pIRT2, pJK148, pON163, pSPl, pSP3, pUR19, pARTl, pCHY21 , REP41, pYZIN, pSLF104, pSLF172, pDS472, pSGP572, pSLF1072, REP41MH-N, pFA6a-kanMX6, pARTCM, and pALL.
  • insect host system and plant cell systems are also included.
  • the present invention is also directed to a combination of an isolated first antibody or antigen binding fragment thereof and an isolated second antibody or antigen binding fragment thereof, wherein both first and second antibodies and antigen binding fragments thereof are raised against the GBS polypeptides described herein.
  • antibodies or antigen-binding fragments, variants, or derivatives thereof of the invention include, but are not limited to, polyclonal antibodies, monoclonal antibodies, chimeric antibodies, multivalent antibodies, multispecif ⁇ c antibodies, single chain antibodies, and fragments produced by a Fab expression library or epitope-binding fragments, e.g., Fab fragments, Fab' fragments, F(ab')2 fragments, Fd fragments, Fv fragments, single-chain Fv fragments (scFv), and disulfide-linked Fv fragments (sdFv).
  • Such fragments include fragments of whole antibodies which retain their binding activity for a target substance, Fv, F(ab') and F(ab') 2 fragments, as well as single chain antibodies (scFv), fusion proteins and other synthetic proteins which comprise the antigen-binding site of the antibody.
  • the antibodies and fragments thereof may be humanized antibodies, for example as described in EP-A-0239400, incorporated herein by reference in its entirety.
  • antibodies with fully human variable regions (or their fragments), for example, as described in US Patents Nos. 5,545,807 and 6,075,181 (both incorporated herein by reference in their entireties) may also be used.
  • Immunoglobulin or antibody molecules of the invention can be of any type ⁇ e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class or subclass ⁇ e.g., IgGl, IgG2a, IgG2b, IgG2c, and IgG3) of immunoglobulin molecule.
  • immunoglobulin or antibody molecules of the invention are IgG2a antibodies.
  • a selected mammal ⁇ e.g., mouse, rabbit, goat, horse, etc.
  • an immunogenic composition comprising the combination of polypeptides or peptides of the present invention.
  • various adjuvants described elsewhere herein, may be used to increase immunological response.
  • Monoclonal antibodies directed against epitopes obtainable from a peptide used in the present invention can also be readily produced by one skilled in the art.
  • the general methodology for making monoclonal antibodies by hybridomas is well known.
  • Antibodies both monoclonal and polyclonal, which are directed against epitopes obtainable from the polypeptides or peptides of the present invention, are particularly useful in diagnosis, and those which are neutralising are useful in passive immunotherapy.
  • Monoclonal antibodies in particular, may be used to raise anti-idiotype antibodies.
  • Anti-idiotype antibodies are immunoglobulins which carry an "internal image" of the substance and/or agent against which protection is desired.
  • the present invention includes a pharmaceutical, vaccine, or immunological composition comprising an isolated first polypeptide and an isolated second polypeptide, wherein the first polypeptide and second polypeptide are selected from the group consisting of the GBS polypeptides described herein.
  • a pharmaceutical, vaccine, or immunological composition which comprises an isolated first polynucleotide and an isolated second polynucleotide, wherein the first polynucleotide and the second polynucleotide are selected from the group consisting of the polynucleotides described herein.
  • the present invention includes an isolated first antibody or antigen binding fragment thereof and an isolated second antibody or antigen binding fragment thereof, wherein the first antibody or antigen binding fragment thereof and the second antibody or antigen binding fragment thereof are selected from the group consisting of the antibodies or antigen binding fragments thereof raised against the GBS polypeptides described herein.
  • the composition of the present invention includes an isolated first polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference amino acid sequence selected from the group consisting of (i) SEQ ID NO: 33; (ii) amino acids 113-192 of SEQ ID NO: 33; (iii) amino acids 71-192 of SEQ ID NO: 33; and (iv) amino acids 24-192 of SEQ ID NO: 33; and an isolated second polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical, to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 68, (ii) amino acids 1-138 of SEQ ID NO: 68; (iii) amino acids 285-363 of SEQ ID NO: 68; (iv) amino acids 210-363 of SEQ ID NO: 68
  • the composition comprises an isolated first polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 21; (ii) amino acids 1-77 of SEQ ED NO: 21; (iii) amino acids 106-225 of SEQ ID NO:21; (iv) amino acids 272-360 of SEQ ID NO:21; and (v) amino acids 106-360 of SEQ ID NO:21; and an isolated second polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 68, (ii) amino acids 1-138 of SEQ ID NO: 68; (iii) amino acids 285-363 of SEQ ID NO: 68; (iv) amino acids 210
  • the first polypeptide and the second polypeptide are not identical and each of the first polypeptide and second polypeptide specifically binds to an antibody raised against a polypeptide consisting of an amino acid sequence identical to the reference amino acid sequence.
  • the pharmaceutical, immunological, or vaccine composition of the present invention comprises an isolated first polynucleotide encoding the first polypeptide and an isolated second polynucleotide encoding the second polypeptide. Furthermore, the composition comprises an isolated first antibody or antigen-binding fragment thereof that specifically binds the first polypeptide described above and an isolated second antibody or antigen-binding fragment thereof that specifically binds the second polypeptide described above.
  • the present invention also includes at least two compositions, wherein a first composition comprises an isolated first polypeptide, polynucleotide, or antibody or antigen binding fragment thereof described herein and a second composition comprises an isolated second polypeptide, polynucleotide, or antibody or antigen binding fragment thereof described herein. Also included is a method of inducing an immune response comprising administering the at least two compositions in an animal in need thereof.
  • the composition comprising the first and second polypeptides further comprises an isolated third polypeptide; the composition comprising the first and second polynucleotides comprises an isolated third polynucleotide; and the composition comprising the first and second antibodies or antigen binding fragments thereof further comprises an isolated third antibody or antigen binding fragment thereof that specifically binds the third polypeptide.
  • the third polynucleotide may encode a third polypeptide.
  • the. third polypeptide may be an antigenic or immunogenic polypeptide. Such antigenic or immunogenic polypeptide may be derived from Group B Streptococcus.
  • the antigenic or immunogenic polypeptide may be the GBS polypeptides, fragments, derivatives, or variants described herein.
  • the composition can comprise any polypeptides disclosed in U.S. Patent Publication No. 2007/0036828, U.S. Patent Publication No. 2006/0275315, and U.S. Patent Publication No. 2006/0258849 (all incorporated herein by reference in their entireties).
  • composition of the present invention further comprising an isolated third polypeptide may therefore comprise an isolated first polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 33; (ii) amino acids 113-192 of SEQ ID NO: 33; (iii) amino acids 71-192 of SEQ DD NO: 33; and (iv) amino acids 24- 192 of SEQ ID NO: 33; an isolated second polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 21; (ii) amino acids 1-77 of SEQ ID NO: 21; (iii) amino acids 106-225 of SEQ ID NO:21; (iv) amino acids 272-360 of S
  • the composition of the present invention comprises two or more of isolated polypeptides, wherein each of said polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from the group consisting of Phol-13, Phol-14, Phol-5, Pho3-3 (phol-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3-29, Pho3-50, MS4, MSI l, MS14, MSlO(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, wherein said polypeptide is recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence.
  • a reference amino acid sequence selected from the group consisting of P
  • the composition comprises two or more of polynucleotides, wherein each of said polynucleotide comprises a nucleic acid sequence at least 80% identical to a reference nucleic acid sequence encoding an amino acid sequence selected from group consisting of Phol- 13, Phol-14, Phol-5, Pho3-3 (phol-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3-29, Pho3-50, MS4, MSl 1, MS14, MSlO(NP GAP, ME:NAP), PBP, pho.3-9, OCT, PGK, and NPGAP, wherein each of said polynucleotide encodes a polypeptide recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence.
  • each of said polynucleotide encodes
  • the composition comprises two or more of vectors, wherein each of said vector encodes a polypeptide comprising an amino acid sequence at least 80% identical to a reference amino acid sequence selected from group consisting of Phol-13, Phol-14, Phol-5, Pho3-3 (phol-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3-29, Pho3-50, MS4, MSI l, MS14, MSlO(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, wherein said polypeptide is recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence.
  • the vector may comprise two or more polynucleotides encoding the two or more polypeptides.
  • the present invention includes a composition comprising isolated antibodies raised against two or more of polypeptides, wherein each of said polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from group consisting of Phol-13, Phol-14, Phol-5, Pho3-3 (phol-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3-29, Pho3-50, MS4, MSI l, MS14, MSlO(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, wherein each of said polypeptide is recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence.
  • a reference amino acid sequence selected from
  • compositions e.g, vaccine compositions, of the present invention can be formulated according to known methods. Suitable preparation methods are described, for example, in Remington 's Pharmaceutical Sciences, 16th Edition, A. Osol, ed., Mack Publishing Co., Easton, PA (1980), and Remington 's Pharmaceutical Sciences, 19th Edition, A.R. Gennaro, ed., Mack Publishing Co., Easton, PA (1995), both of which are incorporated herein by reference in their entireties.
  • the composition may be administered as an aqueous solution, it can also be formulated as an emulsion, gel, solution, suspension, lyophilized form, or any other form known in the art.
  • compositions of the invention can be administered directly to the subject.
  • the subjects to be treated can be animals; in particular, human subjects can be treated.
  • compositions e.g., vaccine, pharmaceutical, or immunological compositions
  • lipopeptides eg.,Vitiello, A. et al, J. Clin. Invest. 95:341, 1995
  • PEG poly(DL-lactide-co-glycolide)
  • concentration of polypeptides of the invention in the compositions of the invention can vary widely, i.e., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
  • compositions in accordance with the invention comprise more than one polypeptide.
  • a composition e.g., a vaccine composition of the present invention can further include a polypeptide selected from the group consisting of, but not limited to, C5a peptidase, ⁇ -component of the C protein, LmbP, Sip, or LrrG as well as more than one GBS polypeptide described herein.
  • the present invention is also directed to a vaccine composition effective against GBS infection further comprising an adjuvant, carrier and/or excipient to the at least two isolated GBS polypeptides.
  • an adjuvant comprising an adjuvant, carrier and/or excipient to the at least two isolated GBS polypeptides.
  • the terms "adjuvant,” “carrier,” and “excipient” overlap to a significant extent.
  • a compound which acts as an "adjuvant” may also be a "carrier,” as well as an “excipient,” and certain other compounds normally thought of, e.g., as carriers, may also function as an adjuvant.
  • adjuvant refers to any material having the ability to (1) alter or increase the immune response to a particular antigen or (2) increase or aid an effect of a pharmacological agent.
  • immunogenic carrier refers to an isolated first polypeptide or fragment, variant, or derivative thereof which enhances the immunogenicity of an isolated second polypeptide or fragment, variant, or derivative thereof.
  • Carriers that can be used with compositions of the invention are well known in the art, and include, without limitation, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B virus core protein, and the like.
  • aqueous carriers may be used, e.g. , water, buffered watery 0.8% saline, 0.3% glycine, hyaluronic acid and the like.
  • These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered.
  • the resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
  • the carrier is an immunogenic carrier.
  • an immunogenic carrier may be fused to or conjugated to a desired polypeptide or fragment thereof. See, e.g., European Patent No. EP 0385610 Bl, which is incorporated herein by reference in its entirety.
  • vaccines which contain immunogenic peptides as active ingredients, is known to one skilled in the art.
  • such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared.
  • the preparation may also be emulsified, or the peptide encapsulated in liposomes.
  • the active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
  • the vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly.
  • Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations.
  • suppositories traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1% to 2%.
  • Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.
  • compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10% to 95% of active ingredient, preferably 25% to 70%.
  • the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is preferably effected in buffer.
  • the peptides of the invention may be formulated into the vaccine as neutral or salt forms.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric and maleic. Salts formed with, the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine and procaine.
  • inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric and maleic.
  • Salts formed with, the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethyl
  • a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient.
  • the dosages below are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.
  • compositions of the present invention may be administered by direct injection.
  • the composition may be formulated for parenteral, mucosal, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.
  • each protein may be administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.
  • polypeptides, polynucleotides, or antibodies or antigen binding fragment thereof of the invention may be administered separately or co-administered to the host subject as a single dose or in multiple doses.
  • the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine before, after, or concurrently with the polypeptides, polynucleotides, or antibody or antigen binding fragment thereof.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine before, after, or concurrently with the polypeptides, polynucleotides, or antibody or antigen binding fragment thereof.
  • Potential adjuvants which may be screened for their ability to enhance the immune response according to the present invention include, but are not limited to: inert carriers, such as alum, bentonite, latex, and acrylic particles; pluronic block polymers, such as TITERMAX ® (block copolymer CRL-8941, squalene (a metabolizable oil) and a microparticulate silica stabilizer), depot formers, such as Freund's adjuvant, surface active materials, such as saponin, lysolecithin, retinal, Quil A, liposomes, and pluronic polymer formulations; macrophage stimulators, such as bacterial lipopolysaccharide; polycationic polymers such as chitosan; alternate pathway complement activators, such as insulin, zymosan, endotoxin, and levamisole; and non-ionic surfactants, such as poloxamers, poly(oxyethylene)-poly(oxypropylene) tri
  • TLR adjuvants include compounds that stimulate the TLRs ⁇ e.g., TLRl - TLRl 7), resulting in an increased immune system response to the vaccine composition of the present invention.
  • TLR adjuvants include, but are not limited to CpG (Coley Pharmaceutical Group Inc.) and MPL (Corixa).
  • CpG Coley Pharmaceutical Group Inc.
  • MPL Corixa
  • One example of a CpG oligonucleotide adjuvant is CpG7909, described in International Pat. Pub. No. WO 98/018810, US Patent Appl. Pub. No. 2002/016434 IA, US Pat. No. 6,727,230, and International Pat. Pub. No. WO98/32462, which are incorporated herein by reference in their entireties.
  • adjuvants and other agents include aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum), beryllium sulfate, silica, kaolin, carbon, water-in- oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, Corynebacterium parvum (Propionobacterium acnes), Bordetella pertussis, polyribonucleotides, sodium alginate, lanolin, lysolecithin, vitamin A, saponin, liposomes, levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants.
  • Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.) N- acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D- isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl- L-alanine-2-(l '-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBITM, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% s
  • adjuvants such as Amphigen (oil-in-water), Alhydrogel
  • aluminum hydroxide or a mixture of Amphigen and Alhydrogel are used. Only aluminum hydroxide is approved for human use.
  • the proportion of immunogen and adjuvant can be varied over a broad range so long as both are present in effective amounts.
  • aluminum hydroxide can be present in an amount of about 0.5% of the vaccine mixture (A12O3 basis).
  • the vaccines are formulated to contain a final concentration of immunogen in the range of from 0.2 to 200 mg/ml, preferably 5 to 50 mg/ml, most preferably 15 mg/ml.
  • more than one adjuvant can be used in the methods and/or the composition.
  • a TLR adjuvant e.g., a CpG oligonucleotide, and Alum together can be formulated with a first polypeptide, polynucleotide, or antibody or antigen-binding fragment thereof, and a second polypeptide, polynucleotide, or antibody or antigen-binding fragment thereof in the methods and compositions of the present. invention.
  • Dosages of the adjuvants can vary according to the specific adjuvants.
  • dosage ranges can include: 10 ⁇ g/dose to 500 ⁇ g/dose, or 50 ⁇ g/dose to 200 ⁇ g/dose for CpG.
  • Dosage ranges can include: 2 ⁇ g/dose to 100 ⁇ g/dose, or 10 ⁇ g/dose to 30 ⁇ g/dose for MPL.
  • Dosage ranges can include: 10 ⁇ g/dose to 500 ⁇ g/dose, or 50 ⁇ g/dose to 100 ⁇ g/dose for aluminum hydroxide.
  • an adjuvant may be used with either the priming immunization, the booster immunization, or both.
  • the adjuvant is a cytokine.
  • Certain compositions of the present invention comprise one or more cytokines, chemokines, or compounds that induce the production of cytokines and chemokines, or a polynucleotide encoding one or more cytokines, chemokines, or compounds that induce the production of cytokines and chemokines.
  • cytokines include, but are not limited to granulocyte macrophage colony stimulating factor (GM- CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M- CSF), colony stimulating factor (CSF), erythropoietin (EPO), interleukin 2 (IL-2), interleukin-3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 9 (IL-9), interleukin 10 (IL-10), interleukin 11 (IL-I l), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 14 (IL-14), interleukin 15 (EL-15), interleukin 16 (IL-16), interleukin 17 (DL-17), interleukin 18 (IL-18), interferon alpha (IFN), interferon beta (IFN), interferon alpha
  • an adjuvant to increase the immune response to an antigen is typically manifested by a significant increase in immune-mediated reaction, or reduction in disease symptoms.
  • an increase in humoral immunity is typically manifested by a significant increase in the titer of antibodies raised to the antigen
  • an increase in T-cell activity is typically manifested in increased cell proliferation, or cellular cytotoxicity, or cytokine secretion.
  • An adjuvant may also alter an immune response, for example, by changing a primarily humoral or Th2 response into a primarily cellular, or Thj response. Immune responses to a given antigen may be tested by various immunoassays well known to those of ordinary skill in the art, and/or described elsewhere herein.
  • the composition of the present invention may further comprise bacterial saccharides, such as the capsular saccharides from a GBS, Neisseria sp., Streptococcus pneumoniae sp. or Haemophilus influenzae type-b bacteria.
  • the saccharide antigen can be conjugated to a carrier molecule.
  • the polypeptides of the invention can also be administered via liposome carriers, which serve to target the polypeptides to a particular tissue, such as lymphoid tissue, or to target selectively to infected cells, as well as to increase the half-life of the polypeptide composition.
  • liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like.
  • the polypeptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to a receptor prevalent among lymphoid cells (such as monoclonal antibodies which bind to the CD45 antigen or other costimulatory factor) or with other therapeutic or immunogenic compositions.
  • a molecule which binds to a receptor prevalent among lymphoid cells such as monoclonal antibodies which bind to the CD45 antigen or other costimulatory factor
  • liposomes either filled or decorated with a desired polypeptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the polypeptide compositions.
  • Liposomes for use in accordance with the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol.
  • lipids are generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream.
  • a variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al, Ann. Rev. Biophys. Bioeng. 9:467 (1980), and U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.
  • a liposome suspension containing a polypeptide of the invention may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the polypeptide being delivered, and the stage of the disease being treated.
  • nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more polypeptides of the invention, often at a concentration of 25%-75%.
  • the immunogenic polypeptides can be supplied in finely divided form, optionally along with a surfactant and, propellant and/or a mucoadhesive, e.g., chitosan.
  • a surfactant e.g., a hydroxybenzoic acid
  • propellant e.g., benzoic acid
  • mucoadhesive e.g., chitosan.
  • Typical percentages of polypeptides are 0.01%-20% by weight, often l%-10%.
  • the surfactant must, of course, be pharmaceutically acceptable, and in some embodiments soluble in the propellant.
  • esters or partial esters of fatty acids containing from 6 to 22 carbon atoms such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride.
  • Mixed esters, such as mixed or natural glycerides may be employed.
  • the surfactant may constitute 0.1%-20% by weight of the composition, in some embodiments 0.25-5% by weight.
  • the balance of the composition is ordinarily propellant, although an atomizer may be used in which no propellant is necessary and other percentages are adjusted accordingly. In.
  • the immunogenic polypeptides can be incorporated within an aerodynamically light particle, such as those particles desc ⁇ bed in U.S. Pat. No. 6,942,868 or U.S. Pat. Pub. No. 2005/0008633.
  • a carrier can also be included, e.g., lecithin for intranasal delivery.
  • Another embodiment of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with the combination of polypeptides, or fragments thereof, adequate to produce antibody and/or T cell immune response to protect the animal from infection by Group B Streptococci.
  • the present invention is directed to a method to induce an immune response in a subject comprising: administering to the animal in need thereof an isolated first polypeptide, polynucleotide, antibody or antigen binding fragment thereof, vector, or host cell described herein and an isolated second polypeptides, polynucleotides, antibody or antigen binding fragment thereof, vectors, or host cells described herein.
  • the subject is an animal, e.g., a mammal, e.g., a primate, e.g., a human.
  • the invention is directed to a method of inducing an immune response, wherein the immune response treats, prevents, or ameliorates a disease or disorder related to GBS in a subject, e.g., a host animal, comprising administering an effective amount of an isolated first polypeptide, polynucleotide, antibody or antigen binding fragment thereof, vector, or host cell described herein and an isolated second polypeptide, polynucleotide, antibody or antigen binding fragment thereof, vector, or host cell described herein.
  • an animal can be treated with a composition comprising at least two different polypeptides, at least two different polynucleotides, vectors comprising the polynucleotides, or host cells comprising the vector prophylactically, e.g., as a prophylactic vaccine, to establish or enhance immunity to one or more GBS serotypes in a healthy animal prior to exposure to GBS or contraction of a GBS symptom, thus preventing the disease or reducing the severity of disease symptoms.
  • the composition may be used to induce an immune response or to treat an animal already exposed to GBS, or already suffering from GBS-related symptom to further stimulate the immune system of the animal, thus reducing or eliminating the symptoms associated with that exposure.
  • the composition of the present invention can be used to provide prophylactic immunity to a neonate.
  • treatment of an animal refers to the use of two or more compositions comprising a single GBS polypeptide, or a composition comprising two or more GBS polypeptides, polynucleotides, vectors, or host cells of the present invention to prevent, cure, retard, or reduce the severity of GBS symptoms in an animal, and/or result in no worsening of GBS symptoms over a specified period of time. It is not required that any composition, polypeptide, polynucleotide, a vector, or a host cell of the present invention provides total protection against GBS infection or totally cure or eliminate all GBS symptoms.
  • an animal in need of therapeutic and/or preventative immunity refers to an animal which it is desirable to treat, i.e., to prevent, cure, retard, or reduce the severity of GBS symptoms, and/or result in no worsening of GBS symptoms over a specified period of time.
  • an antibody specifically reactive with a GBS organism is isolated from the serum of the host animal which has been administered a polypeptide or polynucleotide of the present invention.
  • the invention is directed to a method of providing passive immunity comprising administering the antibody specifically reactive with a GBS organism (which was isolated from the serum of a host animal) to an animal in need thereof.
  • the present invention is directed to a method of inducing an immune response comprising administering an isolated first polypeptide and an isolated second polypeptide, wherein each of the first polypeptide and the second polypeptide is selected from the group consisting of the GBS polypeptides described herein.
  • the first polypeptide and the second polypeptide are not identical and each of the first polypeptide and the second polypeptide specifically binds to an antibody raised against a polypeptide consisting of an amino acid sequence identical to said reference amino acid sequence.
  • the method of inducing an immune response comprises administering an isolated first polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from the group consisting of (i) SEQ ID NO: 33; (ii) amino acids 113-192 of SEQ ID NO: 33; (iii) amino acids 71-192 of SEQ ID NO: 33; and (iv) amino acids 24-192 of SEQ ID NO: 33; and an isolated second polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from the group consisting of (i) SEQ ID NO: 21; (ii) amino acids 1-77 of SEQ ID NO: 21; (iii) amino acids 106- 225 of SEQ ID NO: 21; (iv) amino acids 272-360 of SEQ ID NO: 21; and
  • the method comprises administering an isolated first polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from the group consisting of (i) SEQ ID NO: 33; (ii) amino acids 113-192 of SEQ ID NO: 33; (iii) amino acids 71-192 of SEQ ID NO: 33; and (iv) amino acids 24-192 of SEQ ID NO: 33; and an isolated second polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or ] 00% identical to a.
  • a reference amino acid sequence selected from the group consisting of (i) SEQ ID NO: 33; (ii) amino acids 113-192 of SEQ ID NO: 33; (iii) amino acids 71-192 of SEQ ID NO: 33; and (iv) amino acids 24-192 of SEQ ID NO: 33; and an isolated second poly
  • the method comprises an isolated first polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 21; (ii) amino acids 1-77 of SEQ ID NO: 21; (iii) amino acids 106-225 of SEQ ID NO:21; (iv) amino acids 272-360 of SEQ ID NO:21; and (v) amino acids 106-360 of SEQ ID NO:21; and an isolated second polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to a reference amino acid sequence selected from the group consisting of (i) SEQ ID NO: 68, (ii) amino acids 1-138 of SEQ ID NO: 68; (iii) amino acids 285- 363 of SEQ ID NO: 68; (iv) amino acids
  • the present invention includes a method of inducing immune response comprising further administering an isolated third polypeptide, polynucleotide, or antibody or antigen binding fragment thereof.
  • the third polypeptide, polynucleotide, and antibody or antigen binding fragment thereof are described elsewhere herein.
  • Treatment with the GBS polypeptides, polynucleotides, antibody or antigen binding fragments, or a pharmaceutical composition comprising the same can occur separately or in conjunction with other treatments, as appropriate.
  • compositions, polypeptides or polynucleotides are administered to a patient in an amount sufficient to elicit an effective CTL response to the GBS- derived polypeptide to cure or at least partially arrest symptoms and/or complications.
  • Amounts effective for this use will depend on, e.g., the polypeptide or polynucleotide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization for polypeptide vaccines is (that is for therapeutic or prophylactic administration) from about 1.0 ⁇ g to about 5000 ⁇ g of polypeptide, in some embodiments about 10 ⁇ g to about 30 ⁇ g, for a 70 kg patient, followed by boosting dosages of from about 1.0 ⁇ g to about 1000 ⁇ g, in some embodiments 10 ⁇ g to about 30 ⁇ g, of polypeptide pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition by measuring specific CTL activity in the patient's blood.
  • the dose range for the initial immunization is from about 1.0 ⁇ g to about 20,000 ⁇ g of polypeptide for a 70 kg patient, in some embodiments 2 ⁇ g -, 5 ⁇ g - 10 ⁇ g -, 15 ⁇ g -, 20 ⁇ g.-, 25 ⁇ g -, 30 ⁇ g -, 40 ⁇ g -, or 50 ⁇ g -2000 ⁇ g, followed by boosting dosages in the same dose range pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition by measuring specific CTL (cytotoxic T lymphocytes) activity in the patient's blood.
  • CTL cytotoxic T lymphocytes
  • approximately 0.01 to 2000 ⁇ g, or in some embodiments 2 ⁇ g to 200 ⁇ g or 10 ⁇ g to 30 ⁇ g, of a polypeptide or polynucleotide of the present invention, or its fragment, derivative variant, or analog is administered to a host.
  • the amount of polynucleotide in the initial immunization depends upon a number of factors including, for example, the antigen being expressed, the expression vector being used, the age and weight of the subject, the precise condition requiring treatment and its severity, and the route of administration. Based on the above factors, determining the precise amount, number of doses, and timing of doses are within the ordinary skill in the art and will be readily determined by the attending physician or veterinarian. In some embodiments, doses for nucleic acids encoding polypeptides range from about 10 ng to 1 g, 100 ng to 100 mg, 1 ⁇ g to 10 mg, or 30-300 ⁇ g DNA or RNA per patient. [00349] In non-limiting embodiments of the invention, an effective amount of a composition of the invention produces an elevation of antibody titer to at least three times the antibody titer prior to administration.
  • polypeptides and compositions of the present invention may generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the polypeptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these polypeptide compositions.
  • administration should begin at the first sign of GBS infection. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In chronic infection, loading doses followed by boosting doses may be required.
  • Treatment of an infected individual with the compositions of the invention may hasten resolution of the infection in acutely infected individuals.
  • the compositions are particularly useful in methods for preventing the evolution from acute to chronic infection.
  • the susceptible individuals are identified prior to or during infection, for instance, as described herein, the composition can be targeted to them, minimizing need for administration to a larger population.
  • compositions of the present invention may be administered to any tissue of an animal, including, but not limited to, muscle, skin, brain tissue, lung tissue, liver tissue, spleen tissue, bone marrow tissue, thymus tissue, heart tissue, e.g , myocardium, endocardium, and pericardium, lymph tissue, blood tissue, bone tissue, pancreas tissue, kidney tissue, gall bladder tissue, stomach tissue, intestinal tissue, testicular tissue, ovarian tissue, uterine tissue, vaginal tissue, rectal tissue, nervous system tissue, eye tissue, glandular tissue, tongue tissue, and connective tissue, e.g., cartilage.
  • tissue of an animal including, but not limited to, muscle, skin, brain tissue, lung tissue, liver tissue, spleen tissue, bone marrow tissue, thymus tissue, heart tissue, e.g , myocardium, endocardium, and pericardium, lymph tissue, blood tissue, bone tissue, pancreas tissue, kidney tissue, gall bladder tissue, stomach tissue, intestinal
  • compositions of the present invention may be administered to any internal cavity of a vertebrate, including, but not limited to, the lungs, the mouth, the nasal cavity, the stomach, the peritoneal cavity, the intestine, any heart chamber, veins, arteries, capillaries, lymphatic cavities, the uterine cavity, the vaginal cavity, the rectal cavity, joint cavities, ventricles in brain, spinal canal in spinal cord, the ocular cavities, the lumen of a duct of a salivary gland or a liver.
  • a vertebrate including, but not limited to, the lungs, the mouth, the nasal cavity, the stomach, the peritoneal cavity, the intestine, any heart chamber, veins, arteries, capillaries, lymphatic cavities, the uterine cavity, the vaginal cavity, the rectal cavity, joint cavities, ventricles in brain, spinal canal in spinal cord, the ocular cavities, the lumen of a duct of a salivary gland or a liver.
  • compositions of the present invention When the compositions of the present invention is administered to the lumen of a duct of a salivary gland or a liver, the desired polypeptide is encoded in each of the salivary gland and the liver such that the polypeptide is delivered into the blood stream of the vertebrate from each of the salivary gland and the liver.
  • Certain modes for administration to secretory organs of a gastrointestinal system using the salivary gland, liver and pancreas to release a desired polypeptide into the bloodstream are disclosed in U.S. Patent Nos. 5,837,693 and 6,004,944, both of which are incorporated herein by reference in their entireties.
  • the compositions are administered to muscle, either skeletal muscle or cardiac muscle, or lung tissue.
  • compositions of the present invention are delivered to an animal by methods described herein, thereby achieving an effective immune response, and/or an effective therapeutic or preventative immune response.
  • an effective immune response and/or an effective therapeutic or preventative immune response.
  • Any mode of administration can be used so long as the mode results in the delivery and/or expression of the desired polypeptide in the desired tissue, in an amount sufficient to generate an immune response to GBS, and/or to generate a prophylactically or therapeutically effective immune response to GBS, in an animal in need of such response.
  • compositions of the present invention can be administered by injection, parenterally, for example intravenously, intramuscularly or subcutaneously.
  • parenteral administration the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood.
  • compositions of the present invention can be administered by mucosal delivery, transdermal delivery, subcutaneous injection, intravenous injection, oral administration, pulmonary administration, intramuscular " (i.m.) administration, or via intradural injection.
  • Transdermal delivery includes, but not limited to intradermal (e.g., into the dermis or epidermis), transdermal (e.g., percutaneous) and transmucosal administration (i.e., into or through skin or mucosal tissue).
  • Intracavity administration includes, but not limited to administration into oral, vaginal, rectal, nasal, peritoneal, or intestinal cavities as well as, intrathecal (i.e., into spinal canal), intraventricular (i.e., into the brain ventricles or the heart ventricles), intraatrial (i.e., into the heart atrium) and sub arachnoid (i.e., into the sub arachnoid spaces of the brain) administration.
  • intrathecal i.e., into spinal canal
  • intraventricular i.e., into the brain ventricles or the heart ventricles
  • intraatrial i.e., into the heart atrium
  • sub arachnoid i.e., into the sub arachnoid spaces of the brain
  • the compositions, polypeptides, polynucleotides, or antibody or antigen binding fragment thereof or any of the present invention may also be administered by a transdermal patch, sublingual wafer, or automjection device.
  • Any mode of administration can be used so long as the mode results in the delivery and/or expression of the desired polypeptide in the desired tissue, in an amount sufficient to generate an immune response against GBS, and/or to generate a prophylactically or therapeutically effective immune response against GBS, in an animal in need of such response.
  • Administration means of the present invention include needle injection, catheter infusion, biolistic injectors, particle accelerators (e.g., "gene guns” or pneumatic "needleless” injectors) Med-E-Jet (Vahlsing, H., et al, J. Immunol.
  • gelfoam sponge depots other commercially available depot materials (e.g., hydrogels), osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, topical skin creams, and decanting, use of polynucleotide coated suture (Qin, Y., et al, Life Sciences 65, 2193-2203 (1999)) or topical applications during surgery. Certain modes of administration are intramuscular needle-based injection and pulmonary application via catheter infusion.
  • the immune system of the host responds to the vaccine by producing large amounts of HTLs (helper T lymphocytes) and/or CTLs (cytotoxic T lymphocytes) specific for the desired antigen. Consequently, the host becomes at least partially immune to later infection, or at least partially resistant to developing an ongoing chronic infection.
  • HTLs helper T lymphocytes
  • CTLs cytotoxic T lymphocytes
  • polypeptides or polynucleotides of the present invention stimulate a cell-mediated immune response sufficient for protection of an animal against GBS infection. In other embodiments, polypeptides or polynucleotides of the present invention stimulate both a humoral and a cell-mediated response, the combination of which is sufficient for protection of an animal against GBS protection.
  • components that induce T cell responses are combined with components that induce antibody responses to the target antigen of interest.
  • vaccine compositions of the invention are combined with polypeptides or polynucleotides which induce or facilitate neutralizing antibody responses to the target antigen of interest.
  • One embodiment of such a composition comprises a class I epitope in accordance with the invention, along with a PADRE ® (Epimmune, San Diego, CA) molecule (described, for example, in U.S. Patent Number 5,736,142, which is incorporated herein by reference in its entirety).
  • the polynucleotides of the present invention can be incorporated into the cells of the animal in vivo, and an antigenic amount of the Streptococcus agalactiae-de ⁇ ved polypeptide, or fragments, variants, or derivatives thereof, is produced in vivo.
  • an antigenic amount of the Streptococcus agalactiae-de ⁇ ved polypeptide, or fragments, variants, or derivatives thereof is produced in vivo.
  • the Streptococcus agalactiae-de ⁇ ved polypeptide is expressed in the animal in an amount sufficient to elicit an immune response.
  • Such an immune response might be used, for example, to generate antibodies to GBS for use in diagnostic assays or as laboratory reagents.
  • the present invention further provides a method for generating, enhancing, or modulating a protective and/or therapeutic immune response against GBS in an animal, comprising administering to the animal in need of therapeutic and/or preventative immunity one or more of the compositions, at least two polypeptides, polynucleotides, vectors, host cells, or composition thereof described herein.
  • the polypeptides, polynucleotides, antibody or antigen binding fragments, or compositions of the present invention can be administered to an animal at any time during the lifecycle of the animal to which it is being administered.
  • the composition can be given shortly after birth.
  • administration can occur while other vaccines are being administered, e.g., at birth, 2 months, 4 months, 6 months, 9 months, at 1 year, at 5 years, or at the onset of puberty.
  • administration can occur when the human become sexually active.
  • polypeptides, polynucleotides, antibody or antigen binding fragments thereof, or compositions of the invention can be used in any desired immunization or administration regimen; e.g., in a single administration or alternatively as part of periodic vaccinations such as annual vaccinations, or as in a prime-boost regime wherein the polypeptide or polynucleotide of the present invention is administered either before or after the administration of the same or of a different polypeptide or polynucleotide.
  • one or more compositions of, the present invention can be utilized in a "prime boost" regimen.
  • An example of a "prime boost” regimen may be found in Yang, Z. et al. J. Virol. 77:799-803 (2002), which is incorporated herein by reference in its entirety.
  • one or more polypeptide, polynucleotide, or antibody compositions of the present invention are delivered to an animal, thereby priming the immune response of the animal to a GBS polypeptide of the invention, and then a second immunogenic composition is utilized as a boost vaccination.
  • compositions of the present invention are used to prime immunity, and then a second immunogenic composition, e.g., a recombinant viral vaccine or vaccines, e.g., a recombinant vaccine virus, e.g., a recombinant MVA vaccinia virus, a different polynucleotide vaccine, or one or more purified subunit of the GBS polypeptides or fragments, variants or derivatives thereof is used to boost the anti-GBS immune response.
  • a second immunogenic composition e.g., a recombinant viral vaccine or vaccines, e.g., a recombinant vaccine virus, e.g., a recombinant MVA vaccinia virus, a different polynucleotide vaccine, or one or more purified subunit of the GBS polypeptides or fragments, variants or derivatives thereof is used to boost the anti-GBS immune response.
  • a priming composition and a boosting composition are combined in a single composition or single formulation.
  • a single composition may comprise an isolated GBS polypeptide or a fragment, variant, or derivative thereof as the priming component and a polynucleotide encoding a GBS polypeptide as the boosting component.
  • the compositions may be contained in a single vial where the priming component and boosting component are mixed together.
  • the polynucleotide component may provide a boost to the isolated polypeptide component.
  • compositions comprising both a priming component and a boosting component are referred to herein as "combinatorial vaccine compositions" or “single formulation heterologous prime-boost vaccine compositions.”
  • the priming composition may be administered before the boosting composition, or even after the boosting composition, if the boosting composition is expected to take longer to act.
  • the priming composition may be administered simultaneously with the boosting composition, but in separate formulations where the priming component and the boosting component are separated.
  • At least two GBS polypeptides, polynucleotides, antibody or antigen binding fragments thereof, vectors, or host cells or compositions comprising the same can be administered separately or at the same time.
  • the first polypeptide, polynucleotide, or antibody or antigen-binding fragment thereof may be administered prior to or after the second polypeptide, polynucleotide, or antibody or antigen-binding fragment thereof.
  • the first polypeptide, polynucleotide, or antibody or antigen-binding fragment thereof is administered simultaneously with the second polypeptide, polynucleotide, or antibody or antigen- binding fragment thereof.
  • At least two GBS polypeptides, polynucleotides, antibody or antigen binding fragments thereof, vectors, or host cells or compositions comprising the same may be administered in one or multiple doses.
  • the administering may be performed in at least one dose, at least two doses, at least three doses, at least four doses, at least five doses, at least six doses, at least seven doses, at least eight doses or more.
  • at least three doses may be administered at a first month, at a second month, and at a third month.
  • at least three doses may be at a first month, at a second month, and at a fourth month.
  • At least three doses may be administered at a first month, at a second month, and at a sixth month.
  • the methods may further comprise administration of a fourth dose.
  • the fourth dose may be administered at least once between twelfth and sixtieth month after the administration of the first dose.
  • Pho3-1 (ME:P31), one of the selected proteins, was administered in 47 healthy adult volunteers.
  • the purpose of this trial was to evaluate the safety and immunogenicity of this protein.
  • Pho3-1 (ME:P31) was adjuvanted with alum and tested at four different strengths, with two doses given 28 days apart.
  • Pho3-1 (ME:P31) was immunogenic at all doses tested, the immune response rate was 83% at the lowest dose tested and 100% at the highest dose tested.
  • Pho3-1 (ME:P31) was well tolerated at all dose levels tested, with no serious adverse events reported.
  • the opsonophagocytosis assay will demonstrate opsonisation of GBS with immune sera raised against the proteins and their subsequent uptake by a phagocytic cell line. It is well known to those skilled in the art that this up-take is a precursor to the killing of GBS by the phagocyte.
  • the opsonophagocytosis activity is expressed as a percentage of HL-60 cells (phagocytes) which have taken up fluorescence labeled GBS bacteria.
  • MSlO polypeptide (NPGAP; SEQ ID NO: 68).
  • the sera (individually and in combination) were obtained to opsonise a GBS type Ia/c strain, A909, and measured for the increase in phagocytic uptake mediated by the immune sera compared with the preimmune sera. Antisera against both these candidates could individually mediate a phagocytic uptake. It was also shown that combining equal volumes of the two sera at dilutions >l:100 results in an additive opsonophagocytic effect (See figure 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'obtention d'un vaccin pour améliorer la réponse immunitaire d'un animal ayant besoin d'une protection contre une infection par un Streptococcus du groupe B (GBS). La présente invention porte également sur une composition comprenant deux polypeptides ou plus, ledit polypeptide comprenant une séquence d'acides aminés identique à au moins 80% à la séquence d'acides aminés de référence choisie dans le groupe constitué par Pho1-13, Pho1-14, Pho1-5, Pho3-3 (pho1-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3- 29, Pho3-50, MS4, MS11, MS16, MS14, MS10(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK et NPGAP, un fragment, variant, analogue, ou dérivé de celle-ci, ledit polypeptide étant reconnaissable par une préparation d'anticorps qui se lie spécifiquement à un polypeptide se composant de la séquence d'acides aminés de référence. Dans certains modes de réalisation, la présente invention porte sur un procédé de déclenchement d'une réponse immunitaire dans un hôte comprenant l'administration audit hôte d'une quantité efficace de la composition de la présente invention.
EP07874553A 2006-12-21 2007-12-21 Proteines de streptococcus et leur utilisation comme vaccins Withdrawn EP2104512A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87615606P 2006-12-21 2006-12-21
US98511107P 2007-11-02 2007-11-02
PCT/IB2007/004637 WO2008152448A2 (fr) 2006-12-21 2007-12-21 Protéines et leur utilisation

Publications (1)

Publication Number Publication Date
EP2104512A2 true EP2104512A2 (fr) 2009-09-30

Family

ID=40130254

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07874553A Withdrawn EP2104512A2 (fr) 2006-12-21 2007-12-21 Proteines de streptococcus et leur utilisation comme vaccins

Country Status (2)

Country Link
EP (1) EP2104512A2 (fr)
WO (1) WO2008152448A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
WO2011048041A1 (fr) * 2009-10-19 2011-04-28 Intervet International B.V. Vaccin anti-streptococcique combiné
RU2632651C2 (ru) * 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
EP4272750A3 (fr) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique
EP3600400A4 (fr) 2017-03-28 2021-01-13 The Children's Medical Center Corporation Vaccin contre le staphylococcus aureus à base de système de présentation d'antigènes multiples (maps), composition immunogène et leurs utilisations
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
CN113164580B (zh) 2018-09-12 2025-06-10 儿童医疗中心公司 肺炎球菌融合蛋白疫苗
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281977T3 (es) * 1998-12-22 2007-10-01 Microscience Limited Proteinas de estreptococo del grupo b y su utilizacion.
AU758722B2 (en) * 1998-12-22 2003-03-27 Microscience Limited Outer surface proteins, their genes, and their use
GB0105922D0 (en) * 2001-03-09 2001-04-25 Microscience Ltd Genes and proteins, and their use
EP1663303B1 (fr) * 2003-09-15 2011-05-04 Novartis Vaccines and Diagnostics, Inc. Compositions immunogenes pour streptococcus agalactiae

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008152448A3 *

Also Published As

Publication number Publication date
WO2008152448A2 (fr) 2008-12-18
WO2008152448A3 (fr) 2009-05-22

Similar Documents

Publication Publication Date Title
WO2008152448A2 (fr) Protéines et leur utilisation
AU2010273708B2 (en) Vaccines and compositions against Streptococcus pneumoniae
JP6126993B2 (ja) 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対するワクチン及び組成物
EP1731166A2 (fr) Protéines et vaccins de streptococcus pneumoniae
JP2010500399A (ja) 尿路病原性大腸菌由来の免疫原
CN106794236B (zh) A群链球菌疫苗
CN109456393B (zh) 肺炎链球菌蛋白在抗肺炎链球菌感染中的应用
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
US6887480B1 (en) Streptococcus pneumoniae proteins and vaccines
US7041295B2 (en) Compounds for treatment of infectious and immune system disorders and methods for their use
JP2004520825A (ja) ヘリコバクタータンパク質、核酸およびその使用
JP2002525028A (ja) Ｃｈｌａｍｙｄｉａ抗原および対応するＤＮＡフラグメントおよびそれらの使用
US20210292398A1 (en) Streptococcal toxic shock syndrome
US20100183518A1 (en) Vaccine Against Group A Beta Hemolytic Streptococcus And Respective Process For Obtaining Thereof
US7192590B2 (en) Compounds for treatment of infectious and immune system disorders and methods for their use
CN119343364A (zh) 钩端螺旋体病疫苗
JP2002524034A (ja) Ｃｈｌａｍｙｄｉａ抗原および対応するＤＮＡフラグメントおよびそれらの使用
EA049052B1 (ru) Вакцинная композиция против инфекции streptococcus pneumoniae
KR20230091978A (ko) 면역원성 항원
KR20020025187A (ko) 감염 및 면역계 질환의 치료를 위한 화합물 및 이를이용하는방법
KR20110031343A (ko) 베타-용혈성 스트렙토코커스 균주로부터 유래된 ｏｒｆ1358을 사용하는 조성물 및 방법
MXPA01006663A (es) Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
US20080226661A1 (en) Phage Screening Assay
HK1238144A1 (en) Group a streptococcus vaccine
HK1154514A (en) Compositions and methods of use of orf 554 from beta hemolytic streptococcal strains

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090717

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20100310

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100701